ESMO OPEN 2021 10.1016/j.esmoop.2021.100113

Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours

Paz-Ares¹, L; Barlesi, F; Siena, S; Ahn, MJ; Drilon, A; Conley, A; Rolfo, C; Wolf, J; Seto, T; Doebele, R; Kapre, A; Chen, D; McCallum, S; Osborne, S; Demetri, G

PROCESSES 2021 10.3390/pr9050792

Comprehensive Analysis of Mutation-Based and Expressed Genes-Based Pathways in Head and Neck Squamous Cell Carcinoma

Keam¹, B; Park, JY; Kim, JP; Kim, GD; Yu, YS; Cho, SH; Kim, S; Ahn, HK; Chun, SH; Kwon, JH; Yun, T; Kim, JW; Kim, JE; Ahn, MJ; Kim, JH; Yun, HJ

J THORAC ONCOL 2021 10.1016/j.jtho.2020.12.002

Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations

Passaro¹, A; Mok, T; Peters, S; Popat, S; Ahn, MJ; de Marinis, F

J CLIN ONCOL 2021 10.1200/JCO.20.03025

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer

Dziadziuszko¹, R; Krebs, MG; De Braud, F; Siena, S; Drilon, A; Doebele, RC; Patel, MR; Cho, BC; Liu, SV; Ahn, MJ; Chiu, CH; Farago, AF; Lin, CC; Karapetis, CS; Li, YC; Day, Bm; Chen, D; Wilson, TR; Barlesi, F

CANCER 2021 10.1002/cncr.33571

High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean lung liquid versus invasive biopsy program

Park¹, S; Olsen, S; Ku, BM; Lee, MS; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Choi, YL; Ahn, MJ

J KOREAN NEUROSURG SOC 2021 10.3340/jkns.2020.0135

Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery

Lee¹, MH; Cho, KR; Choi, JW; Kong, DS; Seol, HJ; Nam, DH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Lee, JI

KOREAN J INTERN MED 2021 10.3904/kjim.2019.161

Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer

Lim¹, SH; Sun, JM; Hong, J; Oh, D; Ahn, YC; Chung, MK; Jeong, HS; Son, YI; Ahn, MJ; Baek, CH; Park, K

ANN ONCOL 2021 10.1016/j.annonc.2020.11.020

Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer

Perets¹, R; Bar, J; Rasco, DW; Ahn, MJ; Yoh, K; Kim, DW; Nagrial, A; Satouchi, M; Lee, DH; Spigel, DR; Kotasek, D; Gutierrez, M; Niu, J; Siddiqi, S; Li, X; Cyrus, J; Chackerian, A; Chain, A; Altura, RA; Cho, BC

J NATL CANCER I 2021 10.1093/jnci/djaa063

Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040

Harrington¹, KJ; Soulieres, D; Le Tourneau, C; Dinis, J; Licitra, LF; Ahn, MJ; Soria, A; Machiels, JPH; Mach, N; Mehra, R; Burtness, B; Ellison, MC; Cheng, JD; Chirovsky, DR; Swaby, RF; Cohen, EEW

J CANCER RES CLIN 2021 10.1007/s00432-021-03527-4

Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05

Park¹, JH; You, GL; Ahn, MJ; Kim, SW; Hong, MH; Han, JY; Ock, CY; Lee, JS; Oh, IJ; Lee, SY; Kim, CH; Min, YJ; Choi, YH; Ryu, JS; Park, SH; Ahn, HK; Shim, BY; Lee, KH; Lee, SY; Kim, JS; Yi, J; Choi, SK; An, H; Kang, JH

FUTURE ONCOL 2021 10.2217/fon-2020-1087

Global longitudinal assessment of treatment outcomes in recurrent/metastatic nasopharyngeal carcinoma: GLANCE-NPC study

Ahn¹, MJ; Chirovsky, D; Kuyas, H; Auclair, V; Abounit, S; Joo, S; Shah, R; Yang, MH

J THORAC ONCOL 2021 10.1016/j.jtho.2020.12.009

A Response to the Letter to the Editor: Osimertinib Leads the Way Towards Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases

Lee¹, J; Ahn, MJ

EUR J IMMUNOL 2021 10.1002/eji.202048966

Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer

Ku¹, BM; Kim, Y; Lee, KY; Kim, SY; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

FUTURE ONCOL 2021 10.2217/fon-2020-1119

ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib

Kim¹, ES; Barlesi, F; Mok, T; Ahn, MJ; Shen, JW; Zhang, PK; Ou, SHI

TRANSL LUNG CANCER R 2021 10.21037/tlcr-20-1128

Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors

Kim¹, H; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

ANN PALLIAT MED 2021 10.21037/apm-19-622

Dynamic contrast-enhanced MRI for response evaluation of non-small cell lung cancer in therapy with epidermal growth factor receptor tyrosine kinase inhibitors: a pilot study

Kim¹, JH; Lee, JW; Park, K; Ahn, MJ; Moon, JW; Ham, SY; Yi, CA

CURR OPIN ONCOL 2021 10.1097/CCO.0000000000000698

Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer: is there a role?

Lee¹, J; Ahn, MJ

IMMUNE NETW 2020 10.4110/in.2020.20.e48

Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs

Kim¹, KH; Hur, JY; Koh, J; Cho, J; Ku, BM; Koh, JY; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ; Shin, EC

ANN ONCOL 2020 10.1016/j.annonc.2020.08.2100

Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor AURA3 overall survival analysis

Papadimitrakopoulou¹, VA; Mok, TS; Han, JY; Ahn, MJ; Delmonte, A; Ramalingam, SS; Kim, SW; Shepherd, FA; Laskin, J; He, Y; Akamatsu, H; Theelen, WSME; Su, WC; John, T; Sebastian, M; Mann, H; Miranda, M; Laus, G; Rukazenkov, Y; Wu, YL

SCI REP-UK 2020 10.1038/s41598-020-77036-8

An increase of CD8(+)T cell infiltration following recurrence is a good prognosticator in HNSCC

So¹, YK; Byeon, SJ; Ku, BM; Ko, YH; Ahn, MJ; Son, YI; Chung, MK

J THORAC ONCOL 2020 10.1016/j.jtho.2020.06.018

Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status

Lee¹, J; Choi, YL; Han, J; Park, S; Jung, HA; Su, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

ANN ONCOL 2020 10.1016/j.annonc.2020.08.2234

Osimertinib in central nervous system progressive EGFR-mutant lung cancer do we need to detect T790M?

Park¹, S; Ahn, MJ

EUR J CARDIO-THORAC 2020 10.1093/ejcts/ezaa181

Utility of positron emission-computed tomography for predicting pathological response in resectable oesophageal squamous cell carcinoma after neoadjuvant chemoradiation

Lee¹, J; Choi, JY; Lim, SW; Ahn, MJ; Park, K; Zo, JI; Shim, YM; Oh, D; Sun, JM

SCI REP-UK 2020 10.1038/s41598-020-76130-1

Regulatory -(FoxP3(+)) T cells and TGF-beta predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer

Koh¹, J; Hur, JY; Lee, KY; Kim, MS; Heo, JY; Ku, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

J CLIN ONCOL 2020 10.1200/JCO.20.00505

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer Second Interim Analysis of the Phase III ALTA-1L Trial

Camidge¹, DR; Kim, HR; Ahn, MJ; Yang, JCH; Han, JY; Hochmair, MJ; Lee, KH; Delmonte, A; Garcia Campelo, MR; Kim, DW; Griesinger, F; Felip, E; Califano, R; Spira, A; Gettinger, SN; Tiseo, M; Lin, HM; Gupta, N; Hanley, MJ; Ni, QH; Zhang, PK; Popat, S

TRANSL LUNG CANCER R 2020 10.21037/tlcr-20-379

The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer

Jung¹, HA; Woo, SY; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

BIOLOGY-BASEL 2020 10.3390/biology9100326

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations Are They Different from Those with Common EGFR Mutations?

Jung¹, HA; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K

CANCER RES TREAT 2020 10.4143/crt.2020.245

Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea

Lim¹, SM; Kim, SW; Cho, BC; Kang, JH; Ahn, MJ; Kim, DW; Kim, YC; Lee, JS; Lee, JS; Lee, SY; Park, KU; An, HJ; Cho, EK; Jang, TW; Kim, BS; Kim, JH; Lee, SS; Na, II; Yoo, SS; Lee, KH

ANN ONCOL 2020 10.1016/j.annonc.2020.06.017

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy

Park¹, S; Lee, MH; Seong, M; Kim, ST; Kang, JH; Cho, BC; Lee, KH; Cho, EK; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

J IMMUNOTHER CANCER 2020 10.1136/jitc-2020-001199

Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity

Hong¹, TH; Cha, H; Shim, JH; Lee, B; Chung, J; Lee, C; Kim, NKD; Choi, YL; Hwang, S; Lee, Y; Park, S; Jung, HA; Kim, JY; Park, YH; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH; Park, WY

CANCER RES TREAT 2020 10.4143/crt.2020.278

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation

Park¹, S; Ku, BM; Jung, HA; Sun, JM; Ahn, JS; Lee, SH; Park, K; Ahn, MJ

J THORAC ONCOL 2020 10.1016/j.jtho.2020.06.006

Molecular Testing in Lung Cancer Still Big Gap in Implementation for Real-World Use

Ahn¹, MJ

CANCER 2020 10.1002/cncr.33048

Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy

Park¹, S; Shim, J; Mortimer, PGS; Smith, SA; Godin, RE; Hollingsworth, SJ; Kim, HJ; Jung, HA; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Lee, SH; Park, K

J NEURO-ONCOL 2020 10.1007/s11060-020-03617-2

Diagnostic accuracy of MR imaging of patients with leptomeningeal seeding from lung adenocarcinoma based on 2017 RANO proposal added value of contrast-enhanced 2D axial T2 FLAIR

Seong¹, M; Park, S; Kim, ST; Park, SG; Kim, YK; Kim, HJ; Ahn, MJ

BRIT J CANCER 2020 10.1038/s41416-020-01074-2

Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck

Kim¹, HR; Kang, HN; Yun, MR; Ju, KY; Choi, JW; Jung, DM; Pyo, KH; Hong, MH; Ahn, MJ; Sun, JM; Kim, HS; Kim, J; Yoo, J; Kim, KR; Koh, YW; Kim, SH; Choi, EC; Yoon, SO; Shim, HS; Paik, S; Kim, TM; Cho, BC

LUNG CANCER 2020 10.1016/j.lungcan.2020.05.033

Ten-year patient journey of stage III non-small cell lung cancer patients A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study)

Jung¹, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K

EXPERT OPIN INV DRUG 2020 10.1080/13543784.2020.1804855

Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors

Kim¹, S; Kim, S; Park, YS; Park, JO; Lim, HY; Ahn, JS; Lee, J; Sun, JM; Kang, WK; Han, R; Kim, J; Ahn, MJ

BMC CANCER 2020 10.1186/s12885-020-07214-4

Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer real-world data in Korea

Kim¹, H; Kwon, M; Kim, B; Jung, HA; Sun, JM; Lee, SH; Park, K; Ahn, MJ

LUNG CANCER 2020 10.1016/j.lungcan.2020.05.035

Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer

Jung¹, HA; Noh, JM; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Pyo, H; Ahn, YC; Park, K

SCI REP-UK 2020 10.1038/s41598-020-70168-x

Metabolic radiogenomics in lung cancer associations between FDG PET image features and oncogenic signaling pathway alterations

Kim¹, G; Kim, J; Cha, H; Park, WY; Ahn, JS; Ahn, MJ; Park, K; Park, YJ; Choi, JY; Lee, KH; Lee, SH; Moon, SH

J THORAC DIS 2020 10.21037/jtd.2019.08.29

Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?

Lee¹, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

J THORAC ONCOL 2020 10.1016/j.jtho.2020.05.001

Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic

Dingemans¹, AMC; Soo, RA; Jazieh, AR; Rice, SJ; Kim, YT; Teo, LLS; Warren, GW; Xiao, SY; Smit, EF; Aerts, JG; Yoon, SH; Veronesi, G; De Cobelli, F; Ramalingam, SS; Garassino, MC; Wynes, MW; Behera, M; Haanen, J; Lu, S; Peters, S; Ahn, MJ; Scagliotti, GV; Adjei, AA; Belani, CP

ANN ONCOL 2020 10.1016/j.annonc.2020.04.004

HLA-corrected tumor mutation burden and homologous recombination de fi ciency for the prediction of response to PD -(L)1 blockade in advanced non -small -cell lung cancer patients

Shim¹, JH; Kim, HS; Cha, H; Kim, S; Kim, TM; Anagnostou, V; Choi, YL; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Park, WY; Lee, SH

J CANCER RES CLIN 2020 10.1007/s00432-020-03316-5

Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors Korean cancer study group HN 18-12

Park¹, J; Chun, SH; Lee, YG; Chang, H; Lee, KW; Kim, HR; Shin, SH; An, HJ; Lee, KE; Hwang, IG; Ahn, MJ; Kim, SB; Keam, B

EXPERT OPIN PHARMACO 2020 10.1080/14656566.2020.1798932

Evaluating entrectinib as a treatment option for non-small cell lung cancer

Lee¹, JY; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

CANCER 2020 10.1002/cncr.32809

Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer

Lee¹, J; Kim, HS; Lee, B; Kim, HK; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH

EUR J CANCER 2020 10.1016/j.ejca.2020.03.029

Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma

Lee¹, J; La Choi, Y; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

NAT COMMUN 2020 10.1038/s41467-020-16164-1

Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma

Kim¹, N; Kim, HK; Lee, K; Hong, Y; Cho, JH; Choi, JW; Lee, J; Suh, YL; Ku, BM; Eum, HH; Choi, S; Choi, YL; Joung, JG; Park, WY; Jung, HA; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ; Lee, HO

Journal of thoracic disease 2020 10.21037/jtd.2020.03.23

Adjuvant therapy in stage IIIA-N2 non-small cell lung cancer after neoadjuvant concurrent chemoradiotherapy followed by surgery

Shin¹, S; Kim, HK; Cho, JH; Choi, YS; Kim, K; Kim, J; Zo, JI; Sun, JM; Ahn, MJ; Park, K; Pyo, H; Ahn, YC; Shim, YM

IN VIVO 2020 10.21873/invivo.11920

Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping

Hur¹, JY; Ku, BM; Shim, JH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

JAMA Oncol 2020 10.1001/jamaoncol.2020.0237

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer The MYSTIC Phase 3 Randomized Clinical Trial

Rizvi¹, NA; Cho, BC; Reinmuth, N; Lee, KH; Luft, A; Ahn, MJ; van den Heuvel, MM; Cobo, M; Vicente, D; Smolin, A; Moiseyenko, V; Antonia, SJ; Le Moulec, S; Robinet, G; Natale, R; Schneider, J; Shepherd, FA; Geater, SL; Garon, EB; Kim, ES; Goldberg, SB; Nakagawa, K; Raja, R; Higgs, BW; Boothman, AM; Zhao, L; Scheuring, U; Stockman, PK; Chand, VK; Peters, S

CLIN LUNG CANCER 2020 10.1016/j.cllc.2019.11.006

Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests

Byeon¹, S; Lee, B; Park, WY; Choi, YL; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH

J THEOR BIOL 2020 10.1016/j.jtho.2019.11.004

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Huber¹, RM; Hansen, KH; Rodriguez, LPA; West, HL; Reckamp, KL; Leighl, NB; Tiseo, M; Smit, EF; Kim, DW; Gettinger, SN; Hochmair, MJ; Kim, SW; Langer, CJ; Ahn, MJ; Kim, ES; Kerstein, D; Groen, HJM; Camidge, DR

CELL MOL IMMUNOL 2020 10.1038/s41423-020-0427-6

PD-1 blockade-unresponsive human tumor-infiltrating CD8(+) T cells are marked by loss of CD28 expression and rescued by IL-151

Kim¹, KH; Kim, HK; Kim, HD; Kim, CG; Lee, H; Han, JW; Choi, SJ; Jeong, S; Jeon, M; Kim, H; Koh, J; Ku, BM; Park, SH; Ahn, MJ; Shin, EC

J THORAC ONCOL 2020 10.1016/j.jtho.2019.12.113

Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis

Ahn¹, MJ; Chiu, CH; Cheng, Y; Han, JY; Goldberg, SB; Greystoke, A; Crawford, J; Zhao, YQ; Huang, XN; Johnson, M; Vishwanathan, K; Yates, JWT; Brown, AP; Mendoza-Naranjo, A; Mok, T

INVEST NEW DRUG 2020 10.1007/s10637-019-00795-3

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer

Ku¹, BM; Bae, YH; Lee, KY; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

ANN ONCOL 2020 10.1016/j.annonc.2020.01.013

TATTON: a multi-arm, phase lb trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

Oxnard¹, GR; Yang, JCH; Yu, H; Kim, SW; Saka, H; Horn, L; Goto, K; Ohe, Y; Mann, H; Thress, KS; Frigault, MM; Vishwanathan, K; Ghiorghiu, D; Ramalingam, SS; Ahn, MJ

LANCET ONCOL 2020 10.1016/S1470-2045(19)30785-5

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

Sequist¹, LV; Han, JY; Ahn, MJ; Cho, BC; Yu, H; Kim, SW; Yang, JCH; Lee, JS; Su, WC; Kowalski, D; Orlov, S; Cantarini, M; Verheijen, RB; Mellemgaard, A; Ottesen, L; Frewer, P; Ou, XL; Oxnard, G

J THORAC ONCOL 2020 10.1016/j.jtho.2019.10.022

Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC

Tan¹, WL; Chua, KLM; Lin, CC; Lee, VHF; Tho, LM; Chan, AW; Ho, GF; Reungwetwattana, T; Yang, JC; Kim, DW; Soo, RA; Ahn, YC; Onishi, H; Ahn, MJ; Mok, TSK; Tan, DSW; Yang, F

J THORAC ONCOL 2020 10.1016/j.jtho.2019.11.004

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Huber¹, RM; Hansen, KH; Rodriguez, LPA; West, HL; Reckamp, KL; Leighl, NB; Tiseo, M; Smit, EF; Kim, DW; Gettinger, SN; Hochmair, MJ; Kim, SW; Langer, CJ; Ahn, MJ; Kim, ES; Kerstein, D; Groen, HJM; Camidge, DR

ORAL ONCOL 2020 10.1016/j.oraloncology.2019.104526

Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study

Grunwald¹, V; Chirovsky, D; Cheung, WY; Bertolini, F; Ahn, MJ; Yang, MH; Castro, G; Berrocal, A; Sjoquist, K; Kuyas, H; Auclair, V; Guillaume, X; Joo, S; Shah, R; Harrington, K

J MOL DIAGN 2020 10.1016/j.jmoldx.2019.10.015

Junction Location Identifier (JuLI) Accurate Detection of DNA Fusions in Clinical Sequencing for Precision Oncology

Shin¹, HT; Kim, NKD; Yun, JW; Lee, B; Kyung, S; Lee, KW; Ryu, D; Kim, J; Bae, JS; Park, D; Choi, YL; Lee, SH; Ahn, MJ; Park, K; Park, WY

PLoS One 2020 10.1371/journal.pone.0229299

Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma

Lim¹, JH; Choi, JY; Im, Y; Yoo, H; Jhun, BW; Jeong, BH; Park, HY; Lee, K; Kim, H; Kwon, OJ; Han, J; Ahn, MJ; Kim, J; Um, SW

LANCET ONCOL 2020 10.1016/S1470-2045(19)30690-4

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials

Drilon¹, A; Siena, S; Dziadziuszko, R; Barlesi, F; Krebs, MG; Shaw, AT; de Braud, F; Rolfo, C; Ahn, MJ; Wolf, J; Seto, T; Cho, BC; Patel, MR; Chiu, CH; John, T; Goto, K; Karapetis, CS; Arkenau, HT; Kim, SW; Ohe, Y; Li, YC; Chae, YK; Chung, CH; Otterson, GA; Murakami, H; Lin, CC; Tan, DSW; Prenen, H; Riehl, T; Chow-Maneval, E; Simmons, B; Cui, N; Johnson, A; Eng, S; Wilson, TR; Doebele, RC

J CLIN ONCOL 2020 10.1200/JCO.19.00457

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation?Positive Non?Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

Yang¹, JCH; Kim, SW; Kim, DW; Lee, JS; Cho, BC; Ahn, JS; Lee, DH; Kim, TM; Goldman, JW; Natale, RB; Brown, AP; Collins, B; Chmielecki, J; Vishwanathan, K; Mendoza-Naranjo, A; Ahn, MJ

J CLIN ONCOL 2020 10.1200/JCO.19.00931

Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)

Cho¹, JH; Lim, SH; An, HJ; Kim, KH; Park, KU; Kang, EJ; Choi, YH; Ahn, MS; Lee, MH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Cancer Med 2020 10.1002/cam4.2868

PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence

Byeon¹, S; Cho, JH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

BMC OPHTHALMOL 2020 10.1186/s12886-019-1285-9

Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors

Shin¹, E; Lim, DH; Han, JS; Nam, D; Park, K; Ahn, MJ; Kang, WK; Lee, JY; Ahn, JS; Lee, SH; Sun, JM; Jung, HA; Chung, TY

RESP RES 2020 10.1186/s12931-019-1254-0

Impact of diffusing lung capacity before and after neoadjuvant concurrent chemoradiation on postoperative pulmonary complications among patients with stage IIIA/N2 non-small-cell lung cancer

Shin¹, S; Choi, YS; Jung, JJ; Im, Y; Shin, SH; Kang, D; Cho, JH; Kim, HK; Kim, J; Zo, JI; Shim, YM; Park, K; Ahn, MJ; Ahn, YC; Lee, G; Cho, J; Lee, HY; Park, HY

HEAD NECK-J SCI SPEC 2020 10.1002/hed.26067

Prevalence of NUT carcinoma in head and neck: Analysis of 362 cases with literature review

Lee¹, T; Cho, J; Baek, CH; Son, YI; Jeong, HS; Chung, MK; Hong, SD; Ahn, YC; Oh, DR; Noh, JM; Park, K; Ahn, MJ; Kim, HJ; Kim, YK; Ko, YH

CANCER RES TREAT 2020 10.4143/crt.2019.200

Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies

Ahn¹, MJ; Han, JY; Kim, DW; Cho, BC; Kang, JH; Kim, SW; Yang, JCH; Mitsudomi, T; Lee, JS

CANCER RES TREAT 2020 10.4143/crt.2019.186

Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea

Lee¹, K; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahm, MJ

J Stroke 2020 10.5853/jos.2019.02278

Cancer Related Stroke: An Emerging Subtype of Ischemic Stroke with Unique Pathomechanisms

Bang¹, OY; Chung, JW; Lee, MJ; Seo, WK; Kim, GM; Ahn, MJ

Oncoimmunology 2020 10.1080/2162402X.2020.1722023

Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment

Kim¹, KH; Hur, JY; Cho, J; Ku, BM; Koh, J; Koh, JY; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ; Shin, EC

LANCET ONCOL 2019 10.1016/S1470-2045(19)30504-2

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study

Ahn¹, MJ; Han, JY; Lee, KH; Kim, SW; Kim, DW; Lee, YG; Cho, EK; Kim, JH; Lee, GW; Lee, JS; Min, YJ; Kim, JS; Lee, SS; Kim, HR; Hong, MH; Ahn, JS; Sun, JM; Kim, HT; Lee, DH; Kim, S; Cho, BC

LANCET ONCOL 2019 10.1016/S1470-2045(19)30626-6

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

Kato¹, K; Cho, BC; Takahashi, M; Okada, M; Lin, CY; Chin, K; Kadowaki, S; Ahn, MJ; Hamamoto, Y; Doki, Y; Yen, CC; Kubota, Y; Kim, SB; Hsu, CH; Holtved, E; Xynos, I; Kodani, M; Kitagawa, Y

CANCER 2019 10.1002/cncr.32503

Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer

Papadimitrakopoulou¹, VA; Han, JY; Ahn, MJ; Ramalingam, SS; Delmonte, A; Hsia, TC; Laskin, J; Kim, SW; He, Y; Tsai, CM; Hida, T; Maemondo, M; Kato, T; Jenkins, S; Patel, S; Huang, XN; Laus, G; Markovets, A; Thress, KS; Wu, YL; Mok, T

J THORAC ONCOL 2019 10.1016/j.jtho.2019.06.010

Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC

Antonia¹, SJ; Balmanoukian, A; Brahmer, J; Ou, SHI; Hellmann, MD; Kim, SW; Ahn, MJ; Kim, DW; Gutierrez, M; Liu, SV; Schoffski, P; Jager, D; Jamal, R; Jerusalem, G; Lutzky, J; Nemunaitis, J; Calabro, L; Weiss, J; Gadgeel, S; Bhosle, J; Ascierto, PA; Rebelatto, MC; Narwal, R; Liang, MN; Xiao, F; Antal, J; Abdullah, S; Angra, N; Gupta, AK; Khleif, SN; Segal, NH

EUR J CANCER 2019 10.1016/j.ejca.2019.08.001

Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing

Kim¹, HS; Cha, H; Kim, JH; Park, WY; Choi, YL; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH

J CLIN ONCOL 2019 10.1200/JCO.19.00934

Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

Garon¹, EB; Hellmann, MD; Rizvi, NA; Carcereny, E; Leighl, NB; Ahn, MJ; Eder, JP; Balmanoukian, AS; Aggarwal, C; Horn, L; Patnaik, A; Gubens, M; Ramalingam, SS; Felip, E; Goldman, JW; Scalzo, C; Jensen, E; Kush, DA; Hui, R

STROKE 2019 10.1161/STROKEAHA.119.026373

Circulating DNAs, a Marker of Neutrophil Extracellular Traposis and Cancer-Related Stroke: The OASIS-Cancer Study

Bang¹, OY; Chung, JW; Cho, YH; Oh, MJ; Seo, WK; Kim, GM; Ahn, MJ

J THORAC ONCOL 2019 10.1016/j.jtho.2019.05.033

Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor

Kim¹, Y; Kim, CH; Lee, HY; Lee, SH; Kim, HS; Lee, S; Cha, H; Hong, S; Kim, K; Seo, SW; Sun, JM; Ahn, MJ; Ahn, JS; Park, K

J THORAC ONCOL 2019 10.1016/j.jtho.2019.05.014

DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC

Park¹, S; Lee, H; Lee, B; Lee, SH; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Park, K

KOREAN JOURNAL OF INTERNAL MEDICINE 2019 10.3904/kjim.2017.234

Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Kim¹, MJ; Kim, SM; Jung, HA; Hong, JY; Chang, WJ; Choi, MK; Kim, HS; Sun, JM; Park, K; Ahn, MJ

NAT COMMUN 2019 10.1038/s41467-019-12159-9

DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load

Jung¹, H; Kim, HS; Kim, JY; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Esteller, M; Lee, SH; Choi, JK

J CLIN ONCOL 2019 10.1200/JCO.2017.77.3184

Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial

Cho¹, J; Kim, HS; Ku, BM; Choi, YL; Cristescu, R; Han, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

SCI REP-UK 2019 10.1038/s41598-019-48674-4

Predictive and Prognostic Value of F-18-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer

Moon¹, SH; Sun, JM; Ahn, JS; Park, K; Kim, BT; Lee, KH; Ahn, MJ; Choi, JY

LUNG CANCER 2019 10.1016/j.lungcan.2019.05.024

Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma

Park¹, S; Shim, JH; Lee, B; Cho, I; Park, WY; Kim, Y; Lee, SH; Choi, YL; Han, J; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

PATHOL RES PRACT 2019 10.1016/j.prp.2019.152441

Histopathologic characteristics of advanced-stage ROS1-rearranged non-small-cell lung cancers

Park¹, E; Choi, YL; Ahn, MJ; Han, J

J THORAC ONCOL 2019 10.1016/j.jtho.2019.03.022

Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018

Remon¹, J; Ahn, MJ; Girard, N; Johnson, M; Kim, DW; Lopes, G; Pillai, RN; Solomon, B; Villacampa, G; Zhou, Q

SCI REP-UK 2019 10.1038/s41598-019-45117-y

Prognostic Impact of Longitudinal Monitoring of Radiomic Features in Patients with Advanced Non-Small Cell Lung Cancer

Bak¹, SH; Park, H; Sohn, I; Lee, SH; Ahn, MJ; Lee, HY

CLIN CANCER RES 2019 10.1158/1078-0432.CCR-18-2740

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

Jung¹, KH; LoRusso, P; Burris, H; Gordon, M; Bang, YJ; Hellmann, MD; Cervantes, A; de Olza, MO; Marabelle, A; Hodi, S; Ahn, MJ; Emens, LA; Barlesi, F; Hamid, O; Calvo, E; McDermott, D; Soliman, H; Rhee, I; Lin, R; Pourmohamad, T; Suchomel, J; Tsuhako, A; Morrissey, K; Mahrus, S; Morley, R; Pirzkall, A; Davis, SL

J CANCER RES CLIN 2019 10.1007/s00432-019-02889-0

Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma

Cho¹, JH; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

CLIN LUNG CANCER 2019 10.1016/j.cllc.2018.12.021

Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients

Da Nam¹, B; Kim, TJ; Park, K; Ahn, MJ; Choi, YL; Chung, MJ; Kim, TS; Lee, KS

J THORAC ONCOL 2019 10.1016/j.jtho.2019.01.016

Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC

Barlesi¹, F; Garon, EB; Kim, DW; Felip, E; Han, JY; Kim, JH; Ahn, MJ; Fidler, MJ; Gubens, MA; de Castro, G; Surmont, V; Li, Q; Deitz, AC; Lubiniecki, GM; Herbst, RS

CLIN LUNG CANCER 2019 10.1016/j.cllc.2018.12.020

Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor

Lee¹, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Choi, YL; Ahn, MJ

J THORAC ONCOL 2019 10.1016/j.jtho.2019.03.005

Combination of Osimertinib with Durvalumab in Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: Is There Room for Reinvestigation?

Ahn¹, MJ

J IMMUNOTHER CANCER 2019 10.1186/s40425-019-0609-x

Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma

Park¹, S; Joung, JG; Min, YW; Nam, JY; Ryu, D; Oh, D; Park, WY; Lee, SH; Choi, YL; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

LUNG CANCER 2019 10.1016/j.lungcan.2019.01.012

Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer

Lee¹, K; Kim, Y; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Choi, YL; Sun, JM

CANCER RES TREAT 2019 10.4143/crt.2018.117

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib

Kim¹, Y; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

CLIN CANCER RES 2019 10.1158/1078-0432.CCR-18-1449

The First-week Proliferative Response of Peripheral Blood PD-1(+)CD8(+) T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors

Kim¹, KH; Cho, J; Ku, BM; Koh, J; Sun, JM; Lee, SH; Ahn, JS; Cheon, J; Min, YJ; Park, SH; Park, K; Ahn, MJ; Shin, EC

RADIOTHER ONCOL 2019 10.1016/j.radonc.2019.01.005

Dosimetric predictors for postoperative pulmonary complications in esophageal cancer following neoadjuvant chemoradiotherapy and surgery

Cho¹, WK; Oh, D; Kim, HK; Ahn, YC; Noh, JM; Shim, YM; Zo, JI; Choi, YS; Sun, JM; Lee, SH; Ahn, MJ; Park, K; Nam, H

CANCER RES TREAT 2019 10.4143/crt.2018.324

A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13

Yoo¹, KH; Lee, SJ; Cho, J; Lee, KH; Park, KU; Kim, KH; Cho, EK; Choi, YH; Kim, HR; Kim, HG; Ahn, HJ; Lee, HY; Yun, HJ; Kang, JH; Jeong, J; Choi, MY; Jung, SH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

CANCER RES TREAT 2019 10.4143/crt.2018.151

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea

Byeon¹, S; Kim, Y; Lim, SW; Cho, JH; Park, S; Lee, J; Sun, JM; Choi, YL; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Lancet Respir Med 2019 10.1016/S2213-2600(18)30500-9

Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study

Leigh¹, NB; Hellmann, MD; Hui, RN; Carcereny, E; Felip, E; Ahn, MJ; Eder, JP; Balmanoukian, AS; Aggarwal, C; Horn, L; Patnaik, A; Gubens, M; Ramalingam, SS; Lubiniecki, GM; Zhang, J; Piperdi, B; Garon, EB

CANCER RES TREAT 2019 10.4143/crt.2018.125

EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy

Park¹, SE; Noh, JM; Kim, YJ; Lee, HS; Cho, JH; Lim, SW; Ahn, YC; Pyo, H; Choi, YL; Han, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

CANCER RES TREAT 2019 10.4143/crt.2018.366

Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer

Lee¹, KH; Ahn, YC; Pyo, H; Noh, JM; Park, SG; Kim, TG; Lee, E; Nam, H; Lee, H; Sun, JM; Ahn, JS; Ahn, MJ; Park, K

CANCER 2019 10.1002/cncr.31891

Osimertinib in Patients With T790M Mutation-Positive, Advanced Non-Small Cell Lung Cancer: Long-Term Follow-Up From a Pooled Analysis of 2 Phase 2 Studies

Ahn¹, MJ; Tsai, CM; Shepherd, FA; Bazhenova, L; Sequist, LV; Hida, T; Yang, JCH; Ramalingam, SS; Mitsudomi, T; Janne, PA; Mann, H; Cantarini, M; Goss, G

LUNG CANCER 2019 10.1016/j.lungcan.2018.12.027

Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations

Yang¹, B; Lee, H; Um, SW; Kim, K; Zo, JI; Shim, YM; Kwon, OJ; Lee, KS; Ahn, MJ; Kim, H

CANCER DISCOV 2019 10.1158/2159-8290.CD-18-0839

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

Drilon¹, A; Fu, SQ; Patel, MR; Fakih, M; Wang, D; Olszanski, AJ; Morgensztern, D; Liu, SV; Cho, BC; Bazhenova, L; Rodriguez, CP; Doebele, RC; Wozniak, A; Reckamp, KL; Seery, T; Nikolinakos, P; Hu, ZY; Oliver, JW; Trone, D; McArthur, K; Patel, R; Multani, PS; Ahn, MJ

CLIN NUCL MED 2019 10.1097/RLU.0000000000002394

Pretreatment Tumor 18F-FDG Uptake Improves Risk Stratification Beyond RECIST 1.1 in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer FDG Uptake and Risk Stratification

Moon¹, SH; Sun, JM; Ahn, JS; Park, K; Ahn, MJ; Choi, JY

EUR J NUCL MED MOL I 2019 10.1007/s00259-018-4138-5

Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer

Moon¹, SH; Kim, J; Joung, JG; Cha, H; Park, WY; Ahn, JS; Ahn, MJ; Park, K; Choi, JY; Lee, KH; Kim, BT; Lee, SH

J THORAC ONCOL 2019 10.1016/j.jtho.2018.10.150

Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC

Kim¹, Y; Lee, B; Shim, JH; Lee, SH; Park, WY; Choi, YL; Sun, JM; Ahn, JS; Ahn, MJ; Park, K

ANN ONCOL 2019 10.1093/annonc/mdy545

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial

Herbst¹, RS; Baas, P; Perez-Gracia, JL; Felip, E; Kim, DW; Han, JY; Molina, JR; Kim, JH; Arvis, CD; Ahn, MJ; Majem, M; Fidler, MJ; Surmont, V; de Castro, G; Garrido, M; Shentu, Y; Emancipator, K; Samkari, A; Jensen, EH; Lubiniecki, GM; Garon, EB

CANCER RES TREAT 2019 10.4143/crt.2018.138

Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-Mutated Non-small Cell Lung Cancer

Lee¹, J; Shim, JH; Park, WY; Kim, HK; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ

CANCER RES TREAT 2019 10.4143/crt.2018.012

Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma

Lim¹, SM; Cho, SH; Hwang, IG; Choi, JW; Chang, H; Ahn, MJ; Park, KU; Kim, JW; Ko, YH; Ahn, HK; Cho, BC; Nam, BH; Chun, SH; Hong, JH; Kwon, JH; Choi, JG; Kang, EJ; Yun, T; Lee, KW; Kim, JH; Kim, JS; Lee, HW; Kim, MK; Jung, D; Kim, JE; Keam, B; Yun, HJ; Kim, S; Kim, HR

LANCET 2019 10.1016/S0140-6736(18)31999-8

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Cohen¹, EEW; Soulieres, D; Le Tourneau, C; Dinis, J; Licitra, L; Ahn, MJ; Soria, A; Machiels, JP; Mach, N; Mehra, R; Burtness, B; Zhang, PY; Cheng, J; Swaby, RF; Harrington, KJ

KOREAN JOURNAL OF INTERNAL MEDICINE 2019 10.3904/kjim.2018.179

Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer

Lim¹, SW; Ahn, MJ

RADIAT ONCOL 2018 10.1186/s13014-018-1196-6

Clinical outcomes of radiation therapy for clinical T4b oesophageal cancer with airway invasion

Kim¹, H; Oh, D; Ahn, YC; Park, K; Ahn, MJ; Lee, SH; Sun, JM; Shim, YM; Zo, JI; Choi, YS; Kim, HK; Cho, JH

J CLIN ONCOL 2018 10.1200/JCO.2018.77.7326

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer

Wu¹, YL; Zhang, L; Kim, DW; Liu, XQ; Lee, DH; Yang, JCH; Ahn, MJ; Vansteenkiste, JF; Su, WC; Felip, E; Chia, V; Glaser, S; Pultar, P; Zhao, S; Peng, B; Akimov, M; Tan, DSW

NEW ENGL J MED 2018 10.1056/NEJMoa1810171

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer

Camidge¹, DR; Kim, HR; Ahn, MJ; Yang, JCH; Han, JY; Lee, JS; Hochmair, MJ; Li, JYC; Chang, GC; Lee, KH; Gridelli, C; Delmonte, A; Campelo, RG; Kim, DW; Bearz, A; Griesinger, F; Morabito, A; Felip, E; Califano, R; Ghosh, S; Spira, A; Gettinger, SN; Tiseo, M; Gupta, N; Haney, J; Kerstein, D; Popat, S

CANCER DISCOV 2018 10.1158/2159-8290.CD-18-0484

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibit ROS1/TRK/ALK Solvent-Front Mutations

Drilon¹, A; Ou, SHI; Cho, BC; Kim, DW; Lees, J; Lin, JJ; Zhu, VW; Ahns, MJ; Camidge, DR; Nguyen, J; Zhai, DY; Deng, W; Huang, ZD; Rogers, E; Liu, J; Whitten, J; Lim, JK; Stopatschinskaja, S; Hyman, DM; Doebele, RC; Cui, JJ; Shaw, AT

LUNG CANCER 2018 10.1016/j.lungcan.2018.08.003

Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial

Lim¹, SW; Park, S; Kim, Y; Cho, JH; Park, SE; Lee, H; Kim, HK; Kim, SM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

J CLIN ONCOL 2018 10.1200/JCO.2017.77.5841

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials

Camidge¹, DR; Kim, DW; Tiseo, M; Langer, CJ; Ahn, MJ; Shaw, AT; Huber, RM; Hochmair, MJ; Lee, DH; Bazhenova, LA; Gold, KA; Ou, SHI; West, HL; Reichmann, W; Haney, J; Clackson, T; Kerstein, D; Gettinger, SN

J CLIN ONCOL 2018 10.1200/JCO.2018.77.9363

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

Wu¹, YL; Ahn, MJ; Garassino, MC; Han, JY; Katakami, N; Kim, HR; Hodge, R; Kaur, P; Brown, AP; Ghiorghiu, D; Papadimitrakopoulou, VA; Mok, TSK

J THORAC ONCOL 2018 10.1016/j.jtho.2018.05.026

Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice

Park¹, S; Ahn, BC; Lim, SW; Sun, JM; Kim, HR; Hong, MH; Lee, SH; Ahn, JS; Park, K; La Choi, Y; Cho, BC; Ahn, MJ

J THORAC ONCOL 2018 10.1016/j.jtho.2018.04.038

Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication

Lee¹, H; Lee, HY; Sun, JM; Lee, SN; Kim, Y; Park, SE; Ahn, JS; Park, K; Ahn, MJ

Clin Pharmacol Drug Dev 2018 10.1002/cpdd.427

Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC

Tan¹, EH; Lim, WT; Ahn, MJ; Ng, QS; Ahn, JS; Tan, DSW; Sun, JM; Han, M; Payumo, FC; Mckee, K; Yin, W; Credi, M; Agarwal, S; Jac, J; Park, K

SCI REP-UK 2018 10.1038/s41598-018-27273-9

Deciphering Clinicoradiologic Phenotype for Thymidylate Synthase Expression Status in Patients with Advanced Lung Adenocarcinoma Using a Radiomics Approach

Lee¹, SW; Park, H; Lee, HY; Sohn, I; Lee, SH; Kang, J; Sun, JM; Ahn, MJ

CLIN COLORECTAL CANC 2018 10.1016/j.clcc.2018.01.005

Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer

Lee¹, J; Kim, ST; Park, S; Lee, S; Park, SH; Park, JO; Lim, HY; Ahn, H; Bok, H; Kim, KM; Ahn, MJ; Kang, WK; Park, YS

STROKE 2018 10.1161/STROKEAHA.118.020995

Association of Cancer Cell Type and Extracellular Vesicles With Coagulopathy in Patients With Lung Cancer and Stroke

Chung¹, JW; Cho, YH; Ahn, MJ; Lee, MJ; Kim, GM; Chung, CS; Bang, OY

J CLIN ONCOL 2018 10.1200/JCO.2017.75.5587

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer

Wu¹, YL; Yang, JCH; Kim, DW; Lu, S; Zhou, JY; Seto, T; Yang, JJ; Yamamoto, N; Ahn, MJ; Takahashi, T; Yamanaka, T; Kemner, A; Roychowdhury, D; Paolini, J; Usari, T; Wilner, KD; Goto, K

LUNG CANCER 2018 10.1016/j.lungcan.2018.02.020

Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea

Choi¹, MK; Ahn, JS; Kim, YC; Cho, BC; Oh, IJ; Kim, SW; Lee, JS; Kim, JH; Ahn, MJ; Park, K

PLoS One 2018 10.1371/journal.pone.0194730

Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model

Ku¹, BM; Choi, MK; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Expert Opin Orphan Drugs 2018 10.1080/21678707.2018.1451325

Brigatinib for treatment of anaplastic lymphoma kinase-rearranged metastatic non-small cell lung cancer

Kim¹, HK; Ahn, MJ

J THORAC ONCOL 2018 10.1016/j.jtho.2017.10.014

KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma

Cho¹, JH; Ku, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

J THORAC ONCOL 2018 10.1016/j.jtho.2017.10.007

Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer

Cho¹, JH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

BRIT J CANCER 2018 10.1038/bjc.2017.465

Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07)

Sun¹, JM; Lee, KH; Kim, BS; Kim, HG; Min, YJ; Yi, SY; Yun, HJ; Jung, SH; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

ANN ONCOL 2018 10.1093/annonc/mdx820

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials

Goss¹, G; Tsai, CM; Shepherd, FA; Ahn, MJ; Bazhenova, L; Crino, L; de Marinis, F; Felip, E; Morabito, A; Hodge, R; Cantarini, M; Johnson, M; Mitsudomi, T; Janne, PA; Yang, JCH

LUNG CANCER 2018 10.1016/j.lungcan.2018.01.004

Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy

Park¹, BJ; Cho, JH; Lee, JH; Shin, S; Kim, HK; Choi, YS; Zo, JI; Shim, YM; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Kim, J

Journal of thoracic disease 2018 10.21037/jtd.2018.03.55

Consolidation of immunotherapy becomes new standard of care in unresectable stage III non-small cell lung cancer

Ahn¹, MJ

J THORAC ONCOL 2018 10.1016/j.jtho.2017.10.011

Increased Response Rates to Salvage Chemotherapy Administered after PD-1 /PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer

Park¹, SE; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

Oncoimmunology 2018 10.1080/2162402X.2017.1375642

Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer

Kim¹, HI; Kim, M; Lee, SH; Park, SY; Kim, YN; Kim, H; Jeon, MJ; Kim, TY; Kim, SW; Kim, WB; Kim, SW; Lee, DH; Park, K; Ahn, MJ; Chung, JH; Shong, YK; Kim, WG; Kim, TH

LUNG CANCER 2018 10.1016/j.lungcan.2017.11.020

Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer

Lee¹, J; Kim, HK; Park, BJ; Cho, JH; Choi, YS; Zo, JI; Shim, YM; Pyo, H; Ahn, YC; Ahn, JS; Ahn, MJ; Park, K; Kim, J

J THORAC ONCOL 2018 10.1016/j.jtho.2017.10.003

Cell-free DNA Analysis in SCLC: Ready for Clinical Practice?

Ahn¹, MJ

GENOME RES 2018 10.1101/gr.223263.117

SIDR: simultaneous isolation and parallel sequencing of genomic DNA and total RNA from single cells

Han¹, KY; Kim, KT; Joung, JG; Son, DS; Kim, YJ; Jo, A; Jeon, HJ; Moon, HS; Yoo, CE; Chung, W; Eum, HH; Kim, S; Kim, HK; Lee, JE; Ahn, MJ; Lee, HO; Park, D; Park, WY

INVEST NEW DRUG 2017 10.1007/s10637-017-0463-y

Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors

Lee¹, SJ; Lee, SY; Lee, WS; Yoo, JS; Sun, JM; Lee, J; Park, SH; Park, JO; Ahn, MJ; Lim, HY; Kang, WK; Park, YS

J THORAC ONCOL 2017 10.1016/j.jtho.2017.09.1954

Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer

Sun¹, JM; Noh, JM; Oh, D; Kim, HK; Lee, SH; Choi, YS; Pyo, H; Ahn, JS; Jung, SH; Ahn, YC; Kim, J; Ahn, MJ; Zo, JI; Shim, YM; Park, K

J CLIN ONCOL 2017 10.1200/JCO.2017.73.9250

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses

Mok¹, TSK; Kim, SW; Wu, YL; Nakagawa, K; Yang, JJ; Ahn, MJ; Wang, J; Yang, JCH; Lu, Y; Atagi, S; Ponce, S; Shi, XJ; Rukazenkov, Y; Haddad, V; Thress, KS; Soria, JC

Lancet Respir Med 2017 10.1016/S2213-2600(17)30378-8

Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study

Ahn¹, MJ; Kim, DW; Cho, BC; Kim, SW; Lee, JS; Ahn, JS; Kim, TM; Lin, CC; Kim, HR; John, T; Kao, S; Goldman, JW; Su, WC; Natale, R; Rabbie, S; Harrop, B; Overend, P; Yang, ZF; Yang, JCH

NAT COMMUN 2017 10.1038/s41467-017-01470-y

Prevalence and detection of low-allele-fraction variants in clinical cancer samples

Shin¹, HT; Choi, YL; Yun, JW; Kim, NKD; Kim, SY; Jeon, HJ; Nam, JY; Lee, C; Ryu, D; Kim, SC; Park, K; Lee, E; Bae, JS; Son, DS; Joung, JG; Lee, J; Kim, ST; Ahn, MJ; Lee, SH; Ahn, JS; Lee, WY; Oh, BY; Park, YH; Lee, JE; Lee, KH; Kim, HC; Kim, KM; Im, YH; Park, K; Park, PJ; Park, WY

EXPERT REV MOL DIAGN 2017 10.1080/14737159.2017.1372196

An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer

Ku¹, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

J CLIN ONCOL 2017 10.1200/JCO.2016.71.7629

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer

Govindan¹, R; Szczesna, A; Ahn, MJ; Schneider, CP; Mella, PFG; Barlesi, F; Han, BH; Ganea, DE; Von Pawel, J; Vladimirov, V; Fadeeva, N; Lee, KH; Kurata, T; Zhang, L; Tamura, T; Postmus, PE; Jassem, J; O'Byrne, K; Kopit, J; Li, MS; Tschaika, M; Reck, M

LUNG CANCER 2017 10.1016/j.lungcan.2017.08.017

Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers

Yu¹, HA; Ahn, MJ; Cho, BC; Gerber, DE; Natale, RB; Socinski, MA; Giri, N; Quinn, S; Sbar, E; Zhang, H; Giaccone, G

CANCER RES TREAT 2017 10.4143/crt.2016.442

Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-small Cell Lung Cancer: Elucidation Based on Single Institute Experience

Park¹, H; Oh, D; Ahn, YC; Pyo, H; Noh, JM; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Kim, HK; Choi, YS; Kim, J; Zo, JI; Shim, YM

SCI REP-UK 2017 10.1038/s41598-017-13456-3

Fluorescence-coded DNA Nanostructure Probe System to Enable Discrimination of Tumor Heterogeneity via a Screening of Dual Intracellular microRNA Signatures in situ

Shin¹, SW; Lee, BS; Yang, K; Amornkitbamrung, L; Jang, MS; Ku, BM; Cho, SW; Lee, JH; Bae, H; Oh, BK; Ahn, MJ; Lim, YT; Um, SH

CANCER RES TREAT 2017 10.4143/crt.2016.423

Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study

Park¹, K; Cho, EK; Bello, M; Ahn, MJ; Thongprasert, S; Song, EK; Soldatenkova, V; Depenbrock, H; Puri, T; Orlando, M

CANCER RES TREAT 2017 10.4143/crt.2016.424

Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer

Lee¹, MY; Ku, BM; Kim, HS; Lee, JY; Lim, SH; Sun, JM; Lee, SH; Park, K; Oh, YL; Hong, M; Jeong, HS; Son, YI; Baek, CH; Ahn, MJ

ASIA-PAC J CLIN ONCO 2017 10.1111/ajco.12645

Characteristics and outcomes of ALK plus non-small cell lung cancer patients in Korea

Lim¹, SH; Yoh, KA; Lee, JS; Ahn, MJ; Kim, YJ; Kim, SH; Zhang, J; Patel, D; Swallow, E; Kageleiry, A; Galebach, P; Lee, D; Stein, K; Degun, R; Park, K

CANCER CHEMOTH PHARM 2017 10.1007/s00280-017-3396-4

Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors

Kim¹, HK; Heo, MH; Lee, HS; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

ONCOTARGET 2017

Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer

Ku¹, BM; Bae, YH; Koh, J; Sun, JM; Lee, SSH; Ahn, JS; Park, K; Ahn, MJ

CLIN LUNG CANCER 2017 10.1016/j.cllc.2017.01.005

Association Between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-smokers With NoneSmall-cell Lung Cancer: Analyses From a Prospective Multinational ETS Registry

Soo¹, RA; Kubo, A; Ando, M; Kawaguchi, T; Ahn, MJ; Ou, SHI

J THORAC ONCOL 2017 10.1016/j.jtho.2017.05.019

Scientific Advances in Thoracic Oncology 2016

Soo¹, RA; Stone, ECA; Cummings, KM; Jett, JR; Field, JK; Groen, HJM; Mulshine, JL; Yatabe, Y; Bubendorf, L; Dacic, S; Rami-Porta, R; Detterbeck, FC; Lim, E; Asamura, H; Donington, J; Wakelee, HA; Wu, YL; Higgins, K; Senan, S; Solomon, B; Kim, DW; Johnson, M; Yang, JCH; Sequist, LV; Shaw, AT; Ahn, MJ; Costa, DB; Patel, JD; Horn, L; Gettinger, S; Peters, S; Wynes, MW; Faivre-Finn, C; Rudin, CM; Tsao, A; Baas, P; Kelly, RJ; Leighl, NB; Scagliotti, GV; Gandara, DR; Hirsch, FR; Spigel, DR

J CLIN ONCOL 2017 10.1200/JCO.2016.71.3701

Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement

Lim¹, SM; Kim, HR; Lee, JS; Lee, KH; Lee, YG; JooMin, Y; Cho, EK; Lee, SS; Kim, BS; Choi, MY; Shim, HS; Chung, JH; La Choi, Y; Lee, MJ; Kim, M; Kim, JH; Ali, SM; Ahn, MJ; Cho, BC

J CLIN ONCOL 2017 10.1200/JCO.2016.71.5904

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

Kim¹, DW; Tiseo, M; Ahn, MJ; Reckamp, KL; Hansen, KH; Kim, SW; Huber, RM; West, HL; Groen, HJM; Hochmair, MJ; Leighl, NB; Gettinger, SN; Langer, CJ; Rodriguez, LGPA; Smit, EF; Kim, ES; Reichmann, W; Haluska, FG; Kerstein, D; Camidge, DR

Theranostics 2017 10.7150/thno.19358

Blood Droplet-Based Cancer Diagnosis via Proteolytic Activity Measurement in Cancer Progression

Choi¹, JW; Lee, H; Lee, G; Kim, YR; Ahn, MJ; Park, HJ; Eom, K; Kwon, T

CANCER RES TREAT 2017 10.4143/crt.2016.417

A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma

Lim¹, SH; Shim, YM; Park, SH; Kim, HK; Choi, YS; Ahn, MJ; Park, K; Zo, JI; Sun, JM

WORLD J SURG 2017 10.1007/s00268-017-3908-8

Outcomes of Curative-Intent Surgery and Adjuvant Treatment for Pulmonary Large Cell Neuroendocrine Carcinoma

Kim¹, KW; Kim, HK; Kim, J; Shim, YM; Ahn, MJ; Choi, YL

J Clin Oncol. 2017 Apr 20;35(12):1288-1296. doi: 10.1200/JCO.2016.70.3223. Epub 2017 Feb 21.

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component

Yang JC1¹, Ahn MJ1, Kim DW1, Ramalingam SS1, Sequist LV1, Su WC1, Kim SW1, Kim JH1, Planchard D1, Felip E1, Blackhall F1, Haggstrom D1, Yoh K1, Novello S1, Gold K1, Hirashima T1, Lin CC1, Mann H1, Cantarini M1, Ghiorghiu S1, Janne PA1.

Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9.

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Drilon A1¹, Siena S2,3, Ou SI4, Patel M5, Ahn MJ6, Lee J6, Bauer TM7, Farago AF8, Wheler JJ9, Liu SV10, Doebele R11, Giannetta L2, Cerea G2, Marrapese G2, Schirru M2, Amatu A2, Bencardino K2, Palmeri L2, Sartore-Bianchi A2, Vanzulli A2,3, Cresta S12, Damian S12, Duca M12, Ardini E13, Li G14, Christiansen J14, Kowalski K14, Johnson AD14, Patel R14, Luo D14, Chow-Maneval E14, Hornby Z14, Multani PS14, Shaw AT8, De Braud FG3,12.

Ann Oncol. 2017 Apr 1;28(4):874-881. doi: 10.1093/annonc/mdx008.

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

Hui R1¹, Garon EB2, Goldman JW2, Leighl NB3, Hellmann MD4, Patnaik A5, Gandhi L6, Eder JP7, Ahn MJ8, Horn L9, Felip E10, Carcereny E11, Rangwala R12, Lubiniecki GM12, Zhang J12, Emancipator K12, Roach C13, Rizvi NA14.

Expert Opin Drug Saf. 2017 Apr;16(4):465-469. doi: 10.1080/14740338.2017.1300656. Epub 2017 Mar 8.

EGFR TKI combination with immunotherapy in non-small cell lung cancer

Ahn MJ1¹, Sun JM1, Lee SH1, Ahn JS1, Park K1.

Support Care Cancer. 2017 Mar;25(3):801-809. doi: 10.1007/s00520-016-3463-0. Epub 2016 Nov 8.

Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types

Kim JE1¹, Jang JS2, Kim JW3, Sung YL4, Cho CH5, Lee MA6, Kim DJ7, Ahn MJ8, Lee KY9, Sym SJ10, Lim MC11, Jung H12, Cho EK12, Min KW12.

N Engl J Med. 2017 Feb 16;376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6.

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer

Mok TS1¹, Wu Y-L1, Ahn M-J1, Garassino MC1, Kim HR1, Ramalingam SS1, Shepherd FA1, He Y1, Akamatsu H1, Theelen WS1, Lee CK1, Sebastian M1, Templeton A1, Mann H1, Marotti M1, Ghiorghiu S1, Papadimitrakopoulou VA1; AURA3 Investigators.

Oncotarget. 2017 Feb 28;8(9):15943-15951. doi: 10.18632/oncotarget.13056.

A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)

Kim HR1¹, Jang JS2, Sun JM3, Ahn MJ3, Kim DW4, Jung I5, Lee KH6, Kim JH1, Lee DH7, Kim SW, Cho BC1.

RADIOTHERAPY AND ONCOLOGY, FEB 2017, 122(2):217-223, DOI: 10.1016/j.radonc.2016.09.015

A phase II trial of concurrent chemoradiotherapy with weekly docetaxel plus cisplatin treatment for unresectable locally advanced head and neck cancer

Lee JY¹, Sun JM, Oh D, Lim SH, Chi S, Lee SH, Jung SH, Ahn MJ, Ahn YC, Park K

Expert Opin Pharmacother. 2017 Feb;18(2):225-231. doi: 10.1080/14656566.2017.1285283.

Osimertinib for the treatment of non-small cell lung cancer

Sun JM1¹, Lee SH1, Ahn JS1, Park K1, Ahn MJ1.

Pathol Res Pract. 2017 Feb;213(2):106-112. doi: 10.1016/j.prp.2016.11.012. Epub 2016 Nov 15.

Histologic characteristics of thymic adenocarcinomas: Clinicopathologic study of a nine-case series and a review of the literature

Kwon AY1¹, Han J2, Chu J1, Choi YS3, Jeong BH4, Ahn MJ5, Ahn YC6.

Oncotarget. 2017 Jan 10;8(2):3542-3552. doi: 10.18632/oncotarget.12200.

Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery

Cho WK1¹, Oh D1, Ahn YC1, Shim YM2, Zo JI2, Sun JM3, Ahn MJ3, Park K3.

Clin Lung Cancer. 2017 Jan;18(1):34-42.e2. doi: 10.1016/j.cllc.2016.07.007. Epub 2016 Aug 8.

Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations

Leighl NB1¹, Rizvi NA2, de Lima LG Jr3, Arpornwirat W4, Rudin CM5, Chiappori AA6, Ahn MJ7, Chow LQ8, Bazhenova L9, Dechaphunkul A10, Sunpaweravong P11, Eaton K12, Chen J13, Medley S13, Poondru S13, Singh M13, Steinberg J13, Juergens RA14, Gadgeel SM15.

J Stroke. 2017 Jan;19(1):77-87. doi: 10.5853/jos.2016.00570. Epub 2016 Dec 12.

Hypercoagulability and Mortality of Patients with Stroke and Active Cancer: The OASIS-CANCER Study

Lee MJ1¹, Chung JW1, Ahn MJ2, Kim S3, Seok JM1, Jang HM1, Kim GM1, Chung CS1, Lee KH1, Bang OY1.

EXPERT OPINION ON BIOLOGICAL THERAPY, MAR 3 2016, 16(3):397-406 , DOI: 10.1517/14712598.2016.1145652

Pembrolizumab for the treatment of non-small cell lung cancer

Lim SH¹, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ

Cancer Imaging. 2016 Mar 16;16:5. doi: 10.1186/s40644-016-0063-7.

Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study

Lee JH1¹, Lee HY2, Ahn MJ3, Park K3, Ahn JS3, Sun JM3, Lee KS1.

Radiother Oncol. 2016 Feb;118(2):244-50. doi: 10.1016/j.radonc.2015.11.030. Epub 2015 Dec 17.

Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02)

Lee JY1¹, Sun JM1, Oh DR2, Lim SH1, Goo J3, Lee SH1, Kim SB4, Park KU5, Kim HK6, Hong DS7, Kim JS8, Kim SG9, Yi SY10, Yun HJ11, Hyun MS12, Kim HJ13, Jung SH3, Park K1, Ahn YC14, Ahn MJ15.

Oral Oncol. 2016 Feb;53:10-6. doi: 10.1016/j.oraloncology.2015.11.019. Epub 2015 Dec 19.

Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review

Ahn MJ1¹, D'Cruz A2, Vermorken JB3, Chen JP4, Chitapanarux I5, Dang HQ6, Guminski A7, Kannarunimit D8, Lin TY9, Ng WT10, Park KU11, Chan AT12.

Lung Cancer. 2016 Dec;102:65-73. doi: 10.1016/j.lungcan.2016.10.011. Epub 2016 Oct 27.

Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial

Hanna NH1¹, Kaiser R2, Sullivan RN3, Aren OR4, Ahn MJ5, Tiangco B6, Voccia I7, Pawel JV8, Kovcin V9, Agulnik J10, Gaschler-Markefski B11, Barrueco J12, Sikken P11, Schloss C12, Kim JH13; LUME-Lung 2 Study group.

J Thorac Oncol. 2016 Dec;11(12):2202-2207. doi: 10.1016/j.jtho.2016.07.005. Epub 2016 Jul 14.

Do New pN Subclassifications Proposed by IASLC's Lung Cancer Staging Project Agree with ypN Categories after Trimodality Therapy for Initial N2 Disease?

Kim H1¹, Ahn YC2, Pyo H1, Oh D1, Noh JM1, Sun JM3, Ahn JS3, Ahn MJ3, Park K3, Choi YS4, Kim J4, Zo JI4, Shim YM4, Lee M5, Han J5.

J Thorac Oncol. 2016 Dec;11(12):2051-2052. doi: 10.1016/j.jtho.2016.09.130.

Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" Decision

Ahn MJ1¹, Sun JM2, Lee SH2, Ahn JS2, Park K2.

Asia Pac J Clin Oncol. 2016 Dec;12(4):380-387. doi: 10.1111/ajco.12513. Epub 2016 Jun 17.

An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer

Wang L1¹, Wu YL2, Lu S3, Deng L1, Ahn MJ4, Hsu FM5, Iscoe N6,7, Hossain A8, Puri T9, Zhang P10, Orlando M11.

Sci Transl Med. 2016 Dec 7;8(368):368ra172.

AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases

Yang Z1¹, Guo Q1, Wang Y1, Chen K1, Zhang L1, Cheng Z1, Xu Y1, Yin X1, Bai Y1, Rabbie S2, Kim DW3, Ahn MJ4, Yang JC5, Zhang X6.

BRITISH JOURNAL OF RADIOLOGY, 2016, 89(1067), DOI: 10.1259/bjr.20160109

Value of F-18-FDG heterogeneity for discerning metastatic from benign lymph nodes in nasopharyngeal carcinoma patients with suspected recurrence

Moon SH¹, Cho YS, Son YI, Ahn YC, Ahn MJ, Choi JY, Kim BT, Lee KH

J Thorac Dis. 2016 Nov;8(11):3175-3186. doi: 10.21037/jtd.2016.11.25.

The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations

Cha YK1¹, Lee HY2, Ahn MJ3, Park K3, Ahn JS3, Sun JM3, Choi YL4, Lee KS2.

World Neurosurg. 2016 Nov;95:399-405. doi: 10.1016/j.wneu.2016.08.046. Epub 2016 Aug 24.

Outcomes of Gamma Knife Radiosurgery in Combination with Crizotinib for Patients with Brain Metastasis from Non-Small Cell Lung Cancer

Choi JW1¹, Kong DS1, Seol HJ1, Nam DH1, Yoo KH2, Sun JM2, Ahn JS2, Ahn MJ2, Park K2, Lee JI3.

Cancer. 2016 Oct;122(19):3024-31. doi: 10.1002/cncr.30135. Epub 2016 Jun 17.

Efficacy and Safety of Dovitinib in Pretreated Patients With Advanced Squamous Non-Small Cell Lung Cancer With FGFR1 Amplification: A Single-Arm, Phase 2 Study

Lim SH1¹, Sun JM1, Choi YL2, Kim HR3, Ahn S2, Lee JY1, Lee SH1, Ahn JS1, Park K1, Kim JH3, Cho BC4, Ahn MJ5.

Lung Cancer. 2016 Oct;100:24-29. doi: 10.1016/j.lungcan.2016.07.025. Epub 2016 Jul 26.

Value of volume-based early metabolic response in patients with unresectable thymic epithelial tumor

Moon SH1¹, Kim HS2, Cho YS1, Sun JM3, Ahn JS3, Park K3, Kim BT1, Ahn MJ4, Lee KH5.

TRANSLATIONAL CANCER RESEARCH, OCT 2016, 5:S629-S631, DOI: 10.21037/tcr.2016.10.40

Liquid biopsy in non-small cell lung cancer: come of age

¹,Ahn MJ

Sci Rep. 2016 Jan 21;6:19552. doi: 10.1038/srep19552.

Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck

Huang KK1¹,2, Jang KW3, Kim S4, Kim HS5,6, Kim SM3, Kwon HJ7, Kim HR7, Yun HJ8, Ahn MJ9, Park KU10, Ramnarayanan K2, McPherson JR2,11, Zhang S2, Rhee JK12, Vettore AL2, Das K2, Ishimoto T2, Kim JH5, Koh YW13, Kim SH13, Choi EC13, Teh BT1,2,14, Rozen SG2,11, Kim TM12, Tan P1,2,15, Cho BC5.

Eur J Cancer. 2016 Jan;52:1-9. doi: 10.1016/j.ejca.2015.09.019. Epub 2015 Nov 26.

Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer

Lim SH1¹, Hong M2, Ahn S3, Choi YL3, Kim KM3, Oh D4, Ahn YC4, Jung SH5, Ahn MJ1, Park K1, Zo JI6, Shim YM6, Sun JM7.

Cancer Res Treat. 2016 Jan;48(1):20-7. doi: 10.4143/crt.2014.317. Epub 2015 Mar 2.

Current Status and Challenges of Cancer Clinical Trials in Korea

Shim BY1¹, Park SH2, Lee S3, Kim JS4, Lee KE5, Kang YK6, Ahn MJ2.

Jpn J Clin Oncol. 2016 Jan;46(1):40-5. doi: 10.1093/jjco/hyv163. Epub 2015 Nov 10.

Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy: implication for subgroup selection for induction chemotherapy

Lim SH1¹, Lee SJ1, Ahn MJ1, Park K1, Sun JM2.

J Clin Oncol. 2016 Aug 20;34(24):2866-73. doi: 10.1200/JCO.2015.65.5936. Epub 2016 Jul 18.

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2

Crino L1¹, Ahn MJ2, De Marinis F2, Groen HJ2, Wakelee H2, Hida T2, Mok T2, Spigel D2, Felip E2, Nishio M2, Scagliotti G2, Branle F2, Emeremni C2, Quadrigli M2, Zhang J2, Shaw AT2.

Med Oncol. 2016 Aug;33(8):97. doi: 10.1007/s12032-016-0811-3. Epub 2016 Jul 22.

Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis

Byeon S1¹, Ham JS1, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3.

Invest New Drugs. 2016 Aug;34(4):407-15. doi: 10.1007/s10637-016-0350-y. Epub 2016 Apr 5.

AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells

Ku BM1¹, Bae YH1, Koh J1, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3,4.

PLoS One. 2016 Jul 18;11(7):e0159170. doi: 10.1371/journal.pone.0159170. eCollection 2016.

Cancer Cell-Derived Extracellular Vesicles Are Associated with Coagulopathy Causing Ischemic Stroke via Tissue Factor-Independent Way: The OASIS-CANCER Study

Bang OY1¹,2, Chung JW1,2, Lee MJ1, Kim SJ1, Cho YH2,3, Kim GM1, Chung CS1, Lee KH1, Ahn MJ4, Moon GJ2,3.

Lung Cancer. 2016 Jun;96:48-51. doi: 10.1016/j.lungcan.2016.03.012. Epub 2016 Mar 26.

Assessment of objective responses in thymic epithelial tumors using ITMIG modified criteria

Kim HS1¹, Lee JY2, Lim SH2, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3.

Oncotarget. 2016 Jun 14;7(24):36311-36320. doi: 10.18632/oncotarget.8904.

Targeted sequencing identifies genetic alterations that confer Primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)

Lim SM1¹,2, Kim HR1, Cho EK3, Min YJ4, Ahn JS5, Ahn MJ5, Park K5, Cho BC1, Lee JH6, Jeong HC6, Kim EK6, Kim JH2.

Lung Cancer. 2016 Jun;96:56-62. doi: 10.1016/j.lungcan.2016.03.016. Epub 2016 Mar 29.

Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease

Kim HK1¹, Cho JH1, Choi YS1, Zo JI1, Shim YM1, Park K2, Ahn MJ2, Ahn YC3, Kim K4, Kim J5.

Clin Cancer Res. 2016 May 1;22(9):2139-45. doi: 10.1158/1078-0432.CCR-15-1653. Epub 2015 Dec 14.

A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib

Lee JY1¹, Sun JM1, Lim SH1, Kim HS, Yoo KH1, Jung KS1, Song HN1, Ku BM2, Koh J2, Bae YH2, Lee SH1, Ahn JS1, Park K1, Ahn MJ3.

Cancer Res Treat. 2016 Apr;48(2):527-36. doi: 10.4143/crt.2015.249. Epub 2015 Sep 15.

Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma

Kim HS1¹, Lee JY1, Lim SH1, Park K1, Sun JM1, Ko YH2, Baek CH3, Son YI3, Jeong HS3, Ahn YC4, Lee MY5, Hong M6, Ahn MJ1.

Head Neck. 2016 Apr;38 Suppl 1:E293-9. doi: 10.1002/hed.23988. Epub 2015 Jun 26.

Fate of patients with nasopharyngeal cancer who developed distant metastasis as first failure after definitive radiation therapy

Chang JH1¹,2, Ahn YC1, Park H1, Oh D1, Noh JM1, Sun JM3, Ahn MJ3, Park K3.

Cancer Res Treat. 2016 Apr;48(2):458-64. doi: 10.4143/crt.2015.135. Epub 2015 Oct 14.

Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial

Kang JH1¹, Ahn MJ2, Kim DW3, Cho EK4, Kim JH5, Shin SW6, Wang X7, Kim JS8, Orlando M9, Park K2.

Lancet. 2016 Apr 9;387(10027):1540-50. doi: 10.1016/S0140-6736(15)01281-7. Epub 2015 Dec 19.

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Herbst RS1¹, Baas P2, Kim DW3, Felip E4, Perez-Gracia JL5, Han JY6, Molina J7, Kim JH8, Arvis CD9, Ahn MJ10, Majem M11, Fidler MJ12, de Castro G Jr13, Garrido M14, Lubiniecki GM15, Shentu Y15, Im E15, Dolled-Filhart M15, Garon EB16.

Oncotarget. 2016 Mar 22;7(12):13797-809. doi: 10.18632/oncotarget.7318.

Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation

Kim N1¹,2, Cho A2, Watanabe H3,4, Choi YL2,5, Aziz M6, Kassner M6, Joung JG7, Park AK1,2, Francis JM8, Bae JS7, Ahn SM5, Kim KM5, Park JO9, Park WY2,7, Ahn MJ9, Park K9, Koo J10, Yin HH6, Cho J1,2,7.

Oncotarget. 2016 Mar 22;7(12):14803-13. doi: 10.18632/oncotarget.7543.

The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma

Ku BM1¹, Yi SY2, Koh J1, Bae YH1, Sun JM3, Lee SH3, Ahn JS3, Park K3, Ahn MJ3.

Oncotarget. 2016 Feb 9;7(6):6984-93. doi: 10.18632/oncotarget.6874.

Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)

Lee JY1¹, Qing X2, Xiumin W2, Yali B2, Chi S3, Bak SH4, Lee HY5, Sun JM1, Lee SH1, Ahn JS1, Cho EK6, Kim DW7, Kim HR8, Min YJ9, Jung SH3, Park K1, Mao M2, Ahn MJ1.

J Clin Oncol. 2016 Feb 10;34(5):511-2. doi: 10.1200/JCO.2015.64.2496. Epub 2015 Dec 28.

Prognostic and Predictive Roles of Thymidylate Synthase Expression in Lung Cancer: The Debate Is Still Open Reply

Giovannetti E1¹, Zucali PA2, Rolfo C3, Assaraf YG4, Peters GJ5.

PLoS Genet. 2015 Aug 21;11(8):e1005467. doi: 10.1371/journal.pgen.1005467. eCollection 2015.

Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer

Ji JH1¹, Oh YL2, Hong M2, Yun JW3, Lee HW2, Kim D4, Ji Y4, Kim DH4, Park WY3, Shin HT3, Kim KM2, Ahn MJ5, Park K5, Sun JM5.

J Clin Oncol. 2015 Aug 1;33(22):2450-6. doi: 10.1200/JCO.2014.59.9324. Epub 2015 Jun 29.

Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial

Sun JM1¹, Ahn JS1, Jung SH1, Sun J1, Ha SY1, Han J1, Park K1, Ahn MJ2.

J Clin Oncol. 2015 Aug 20;33(24):2660-6. doi: 10.1200/JCO.2014.60.0130. Epub 2015 Jul 6.

Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04

Ahn JS1¹, Ahn YC1, Kim JH1, Lee CG1, Cho EK1, Lee KC1, Chen M1, Kim DW1, Kim HK1, Min YJ1, Kang JH1, Choi JH1, Kim SW1, Zhu G1, Wu YL1, Kim SR1, Lee KH1, Song HS1, Choi YL1, Sun JM1, Jung SH1, Ahn MJ1, Park K2.

J Thorac Oncol. 2015 Jun;10(6):903-9. doi: 10.1097/JTO.0000000000000535.

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors

Lee JY1¹, Ku BM, Lim SH, Lee MY, Kim H, Kim M, Kim S, Jung HA, Sun JM, Ahn JS, Park K, Ahn MJ.

World J Gastroenterol. 2015 Apr 14;21(14):4268-74. doi: 10.3748/wjg.v21.i14.4268.

Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma

Lee MY1¹, Jung KS1, Kim HS1, Lee JY1, Lim SH1, Kim M1, Jung HA1, Kim SM1, Sun JM1, Ahn MJ1, Lee J1, Park SH1, Yi SY1, Hwang IG1, Lee SC1, Ahn HK1, Lim DH1, Lee SI1, Park KW1.

Oncotarget. 2015 Dec 29;6(42):44971-84. doi: 10.18632/oncotarget.6056.

Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma

Kim HS1¹, Kim SM2, Kim H3, Pyo KH2, Sun JM4, Ahn MJ4, Park K4, Keam B5, Kwon NJ6, Yun HJ7, Kim HG8, Chung IJ9, Lee JS10, Lee KH11, Kim DJ12, Lee CG13, Hur J14, Chung H15, Park JC15, Shin SK15, Lee SK15, Kim HR1, Moon YW1, Lee YC15, Kim JH1, Paik S16,17, Cho BC1.

J Thorac Oncol. 2015 Dec;10(12):1800-6. doi: 10.1097/JTO.0000000000000692.

A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors

Kim HS1¹, Lee JY, Lim SH, Sun JM, Lee SH, Ahn JS, Park K, Moon SH, Ahn MJ.

Lung Cancer. 2015 Nov;90(2):261-6. doi: 10.1016/j.lungcan.2015.08.020. Epub 2015 Sep 4.

Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs

Lee SJ1¹, Sun JM1, Lee SH1, Ahn JS1, Park K1, Ahn MJ2.

J Neurooncol. 2015 Nov;125(2):331-8. doi: 10.1007/s11060-015-1915-x. Epub 2015 Sep 15.

Outcome of gamma knife radiosurgery for metastatic brain tumors derived from non-small cell lung cancer

Cho KR1¹, Lee MH1, Kong DS1, Seol HJ1, Nam DH1, Sun JM2, Ahn JS2, Ahn MJ2, Park K2, Kim ST3, Lim do H4, Lee JI5.

Ann Oncol. 2015 Oct;26(10):2066-72. doi: 10.1093/annonc/mdv288. Epub 2015 Jul 7.

A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)

Yoshioka H1¹, Azuma K2, Yamamoto N3, Takahashi T4, Nishio M5, Katakami N6, Ahn MJ7, Hirashima T8, Maemondo M9, Kim SW10, Kurosaki M11, Akinaga S11, Park K7, Tsai CM12, Tamura T13, Mitsudomi T14, Nakagawa K15.

Cancer Res Treat. 2015 Oct;47(4):645-52. doi: 10.4143/crt.2014.144. Epub 2015 Feb 12.

Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer

Noh JM1¹, Ahn YC1, Lee H2, Pyo H1, Kim B1, Oh D1, Park H1, Lee E1, Park K3, Ahn JS3, Ahn MJ3, Sun JM3.

ONCOTARGET, OCT 13 2015, 6(31), 30929-30938, 10.18632/oncotarget.5131

Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer

Park S¹, Langley E, Sun JM, Lockton S, Ahn JS, Jain A, Park K, Singh S, Kim P, Ahn MJ

Oncotarget. 2015 Oct 20;6(32):33358-68. doi: 10.18632/oncotarget.5188.

The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis

Kim ST1¹, Lee J1, Hong M2,3, Park K4,5, Park JO1, Ahn T3,4, Park SH1, Park YS1, Lim HY1, Sun JM1, Ahn JS1, Ahn MJ1, Kim HC6, Sohn TS6, Choi DI7, Cho JH8, Heo JS6, Kwon W6, Uhm SW9, Lee H10, Min BH10, Hong SN10, Kim DH5,11, Jung SH12, Park W4,5, Kim KM2,3, Kang WK1, Park K1,2.

Ann Oncol. 2015 Jan;26(1):161-6. doi: 10.1093/annonc/mdu504. Epub 2014 Oct 29.

Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing

Sun JM1¹, Choi YL2, Ji JH3, Ahn JS1, Kim KM2, Han J2, Ahn MJ1, Park K4.

AJR Am J Roentgenol. 2015 Sep;205(3):623-8. doi: 10.2214/AJR.14.13847.

Volume-Based Assessment With F-18-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer

Hyun SH1¹, Ahn HK2, Ahn MJ3, Ahn YC4, Kim J5, Shim YM5, Choi JY1.

Lancet Oncol. 2015 Aug;16(8):990-8. doi: 10.1016/S1470-2045(15)00121-7. Epub 2015 Jul 6.

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation- positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

Soria JC1¹, Wu YL2, Nakagawa K3, Kim SW4, Yang JJ2, Ahn MJ5, Wang J6, Yang JC7, Lu Y8, Atagi S9, Ponce S10, Lee DH4, Liu Y11, Yoh K12, Zhou JY13, Shi X14, Webster A15, Jiang H14, Mok TS16.

Cancer Res Treat. 2015 Jul;47(3):424-35. doi: 10.4143/crt.2013.266. Epub 2014 Sep 15.

Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT

Yang JC1¹, Ahn MJ2, Nakagawa K3, Tamura T4, Barraclough H5, Enatsu S6, Cheng R7, Orlando M8.

Cancer Chemother Pharmacol. 2015 Jun;75(6):1229-36. doi: 10.1007/s00280-015-2740-9. Epub 2015 Apr 23.

A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test

Choi MK1¹, Hong JY, Chang WJ, Kim MJ, Kim SM, Jung HA, Do IG, Choi YL, Sun JM, Ahn JS, Park K, Ahn MJ.

Clin Exp Otorhinolaryngol. 2015 Jun;8(2):142-8. doi: 10.3342/ceo.2015.8.2.142. Epub 2015 May 13.

Prognostic Value of Volume-Based Positron Emission Tomography/Computed Tomography in Patients With Nasopharyngeal Carcinoma Treated With Concurrent Chemoradiotherapy

Moon SH1¹, Choi JY1, Lee HJ1, Son YI2, Baek CH2, Ahn YC3, Ahn MJ4, Park K4, Kim BT1.

J Clin Oncol. 2015 Jun 10;33(17):1881-8. doi: 10.1200/JCO.2014.59.0539. Epub 2015 Jan 26.

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases

Costa DB1¹, Shaw AT2, Ou SH2, Solomon BJ2, Riely GJ2, Ahn MJ2, Zhou C2, Shreeve SM2, Selaru P2, Polli A2, Schnell P2, Wilner KD2, Wiltshire R2, Camidge DR2, Crin? L2.

Ann Oncol. 2015 May;26(5):894-901. doi: 10.1093/annonc/mdv072. Epub 2015 Feb 26.

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

Blumenschein GR Jr1¹, Smit EF2, Planchard D3, Kim DW4, Cadranel J5, De Pas T6, Dunphy F7, Udud K8, Ahn MJ9, Hanna NH10, Kim JH11, Mazieres J12, Kim SW13, Baas P14, Rappold E15, Redhu S15, Puski A16, Wu FS15, J?nne PA17.

Clin Lung Cancer. 2015 May;16(3):228-36. doi: 10.1016/j.cllc.2014.11.002. Epub 2014 Nov 18.

Survival Outcome Assessed According to Tumor Burden and Progression Patterns in Patients With Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma Undergoing Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

Cha YK1¹, Lee HY2, Ahn MJ3, Choi YL4, Lee JH1, Park K3, Lee KS1.

Head Neck. 2015 May;37(5):E66-9. doi: 10.1002/hed.23884. Epub 2015 Mar 29.

Presence of anaplastic lymphoma kinase translocation in sarcomatoid carcinoma of head and neck and treatment effect of crizotinib: A case series

Kim SM1¹, Kim MJ, Jung HA, Sun JM, Choi YL, Ko YH, Park K, Baek CH, Son YI, Ahn MJ.

N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19.

Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer

Garon EB1¹, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L; KEYNOTE-001 Investigators.

N Engl J Med. 2015 Apr 30;372(18):1689-99. doi: 10.1056/NEJMoa1411817.

AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer

Janne PA1¹, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M.

World J Gastroenterol. 2015 Apr 14;21(14):4268-74. doi: 10.3748/wjg.v21.i14.4268.

Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma

Lee MY1¹, Jung KS1, Kim HS1, Lee JY1, Lim SH1, Kim M1, Jung HA1, Kim SM1, Sun JM1, Ahn MJ1, Lee J1, Park SH1, Yi SY1, Hwang IG1, Lee SC1, Ahn HK1, Lim do H1, Lee SI1, Park KW1.

Ann Oncol. 2015 Apr;26(4):762-8. doi: 10.1093/annonc/mdu584. Epub 2014 Dec 23.

A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer

Lim SH1¹, Lee JY1, Lee MY1, Kim HS1, Lee J1, Sun JM1, Ahn JS1, Um SW2, Kim H2, Kim BS3, Kim ST4, Na DL5, Sun JY6, Jung SH7, Park K1, Kwon OJ2, Lee JI3, Ahn MJ8.

Pharmacogenomics. 2015;16(4):383-91. doi: 10.2217/pgs.15.14.

Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients

Woo HI1¹, Kim JA, Jung HA, Kim KK, Lee JY, Sun JM, Ahn JS, Park K, Lee SY, Ahn MJ.

J Thorac Oncol. 2015 Feb;10(2):331-7. doi: 10.1097/JTO.0000000000000388.

Endobronchial Ultrasound versus Mediastinoscopy for Mediastinal Nodal Staging of Non-Small-Cell Lung Cancer

Um SW1¹, Kim HK, Jung SH, Han J, Lee KJ, Park HY, Choi YS, Shim YM, Ahn MJ, Park K, Ahn YC, Choi JY, Lee KS, Suh GY, Chung MP, Kwon OJ, Kim J, Kim H.

Invest New Drugs. 2015 Feb;33(1):12-21. doi: 10.1007/s10637-014-0163-9. Epub 2014 Oct 25.

BYL719, a selective inhibitor of phosphoinositide 3-Kinase alpha, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer

Ku BM1¹, Jho EH, Bae YH, Sun JM, Ahn JS, Park K, Ahn MJ.

Lung Cancer. 2015 Feb;87(2):148-54. doi: 10.1016/j.lungcan.2014.11.013. Epub 2014 Nov 29.

Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: A retrospective analysis in Korea

Baek JH1¹, Sun JM2, Min YJ3, Cho EK4, Cho BC5, Kim JH5, Ahn MJ2, Park K2.

Clin Cancer Res. 2015 Feb 1;21(3):544-52. doi: 10.1158/1078-0432.CCR-14-1756. Epub 2014 Nov 25.

Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck

Kim HS1¹, Kwon HJ2, Jung I3, Yun MR4, Ahn MJ5, Kang BW6, Sun JM5, Kim SB7, Yoon DH7, Park KU8, Lee SH9, Koh YW10, Kim SH10, Choi EC10, Koo DH11, Sohn JH12, Kim B13, Kwon NJ14, Yun HJ15, Lee MG16, Lee JH17, Kim TM18, Kim HR19, Kim JH19, Paik S20, Cho BC21.

Eur J Cancer. 2014 Sep;50(13):2219-30. doi: 10.1016/j.ejca.2014.05.011. Epub 2014 Jun 18.

First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial

Yang JC1¹, Kang JH2, Mok T3, Ahn MJ4, Srimuninnimit V5, Lin CC1, Kim DW6, Tsai CM7, Barraclough H8, Altug S9, Orlando M10, Park K11.

Cancer Chemother Pharmacol. 2014 Jun;73(6):1217-25. doi: 10.1007/s00280-014-2458-0. Epub 2014 Apr 3.

Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease

Choi MK1¹, Hong JY, Chang W, Kim M, Kim S, Jung HA, Lee SJ, Park S, Chung MP, Sun JM, Park K, Ahn MJ, Ahn JS.

Ann Surg Oncol. 2014 Jun;21(6):2083-90. doi: 10.1245/s10434-014-3540-x. Epub 2014 Feb 13.

Pretreatment Clinical Mediastinal Nodal Bulk and Extent do not Influence Survival in N2-Positive Stage IIIA Non-small Cell Lung Cancer Patients Treated with Trimodality Therapy

Lee H1¹, Ahn YC, Pyo H, Kim B, Oh D, Nam H, Lee E, Sun JM, Ahn JS, Ahn MJ, Park K, Choi YS, Kim J, Zo JI, Shim YM.

Lung Cancer. 2014 Apr;84(1):51-5. doi: 10.1016/j.lungcan.2014.01.017. Epub 2014 Jan 28.

A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): Paclitaxel plus carboplatin versus vinorelbine plus cisplatin

Chang WJ1¹, Sun JM2, Lee JY1, Ahn JS1, Ahn MJ1, Park K1.

CANCER IMAGING, APR 22 2014, 14, 10.1186/1470-7330-14-2

Prognostic value of volumetric metabolic parameters measured by [F-18]Fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer

Park¹, SB, Choi, JY, Moon, SH, Yoo, J, Kim, H, Ahn, YC, Ahn, MJ, Park, K, Kim, BT

Anticancer Res. 2014 Feb;34(2):707-14.

Assessment of Intratumoral Heterogeneity of Oncogenic Driver Mutations in Surgically-resected Lung Adenocarcinoma: Implications of Percutaneous Biopsy-based Molecular Assay for Target-directed Therapy

Kim HK1¹, Lee HY, Choi YL, Choi SJ, Choi H, Lee J, Han J, Ahn MJ, Lee KS, Kim J.

PLoS One. 2014 Feb 26;9(2):e88598. doi: 10.1371/journal.pone.0088598. eCollection 2014.

Quantitative CT Variables Enabling Response Prediction in Neoadjuvant Therapy with EGFR-TKIs: Are They Different from Those in Neoadjuvant Concurrent Chemoradiotherapy

Chong Y1¹, Kim JH1, Lee HY1, Ahn YC2, Lee KS1, Ahn MJ3, Kim J4, Shim YM4, Han J5, Choi YL5.

J Thorac Oncol. 2014 Oct;9(10):1523-31. doi: 10.1097/JTO.0000000000000275.

Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non-Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib A Phase I/II Trial

Park K1¹, Cho BC, Kim DW, Ahn MJ, Lee SY, Gernhardt D, Taylor I, Campbell AK, Zhang H, Giri N, Letrent SP, O'Connell J, Heo DS.

J Transl Med. 2014 Oct 25;12:299. doi: 10.1186/s12967-014-0299-6.

High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma

Ku BM¹, Jung HA, Sun JM, Ko YH, Jeong HS, Son YI, Baek CH, Park K, Ahn MJ.

J Clin Oncol. 2014 Jan 10;32(2):121-8. doi: 10.1200/JCO.2013.50.8556. Epub 2013 Dec 9.

Integrative and Comparative Genomic Analysis of Lung Squamous Cell Carcinomas in East Asian Patients

Kim Y1¹, Hammerman PS, Kim J, Yoon JA, Lee Y, Sun JM, Wilkerson MD, Pedamallu CS, Cibulskis K, Yoo YK, Lawrence MS, Stojanov P, Carter SL, McKenna A, Stewart C, Sivachenko AY, Oh IJ, Kim HK, Choi YS, Kim K, Shim YM, Kim KS, Song SY, Na KJ, Choi YL, Hayes DN, Kim J, Cho S, Kim YC, Ahn JS, Ahn MJ, Getz G, Meyerson M, Park K.

Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):50-8. doi: 10.1007/s00259-013-2530-8. Epub 2013 Aug 16.

Volume-based assessment by F-18-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer

Hyun SH1¹, Ahn HK, Kim H, Ahn MJ, Park K, Ahn YC, Kim J, Shim YM, Choi JY.

Oncologist. 2014 Jul;19(7):702-3. doi: 10.1634/theoncologist.2013-0419. Epub 2014 May 27.

Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR

Ahn MJ1¹, Kim SW2, Cho BC3, Ahn JS1, Lee DH2, Sun JM1, Massey D4, Kim M5, Shi Y6, Park K7.

Cancer Chemother Pharmacol.?2014 May;73(5):1063-70. doi: 10.1007/s00280-014-2442-8. Epub 2014 Mar 25.

Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs

Lee JY1¹,?Lim SH,?Kim M,?Kim S,?Jung HA,?Chang WJ,?Choi MK,?Hong JY,?Lee SJ,?Sun JM,?Ahn JS,?Park K,?Ahn MJ.

Ann Oncol. 2014 May;25(5):1044-52. doi: 10.1093/annonc/mdu098. Epub 2014 Feb 27.

Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial

Barlesi F1¹, Scherpereel A, Gorbunova V, Gervais R, Vikstr?m A, Chouaid C, Chella A, Kim JH, Ahn MJ, Reck M, Pazzola A, Kim HT, Aerts JG, Morando C, Loundou A, Groen HJ, Rittmeyer A.

J Thorac Oncol. 2014 Apr;9(4):506-11. doi: 10.1097/JTO.0000000000000095.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non-Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either Exon 19 or 21

Lim SH1¹, Lee JY, Sun JM, Ahn JS, Park K, Ahn MJ.

J Mol Diagn. 2014 Mar;16(2):229-43. doi: 10.1016/j.jmoldx.2013.11.007. Epub 2014 Jan 10.

A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer

Lira ME1¹, Choi YL2, Lim SM3, Deng S1, Huang D1, Ozeck M1, Han J4, Jeong JY5, Shim HS5, Cho BC3, Kim J6, Ahn MJ7, Mao M8.

Lung Cancer. 2014 Feb;83(2):259-64. doi: 10.1016/j.lungcan.2013.11.009. Epub 2013 Nov 20.

Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma

Sun JM1¹, Lira M2, Pandya K2, Choi YL3, Ahn JS1, Mao M2, Han J3, Park K1, Ahn MJ4, Kim J5.

When the Abstract Reports a Well-Tolerated Treatment, the Data Should Support It Reply

Lung Cancer. 2013 Dec;82(3):455-60. doi: 10.1016/j.lungcan.2013.08.027. Epub 2013 Sep 8.

A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy

Ahn JS1¹, Lee KH, Sun JM, Park K, Kang ES, Cho EK, Lee DH, Kim SW, Lee GW, Kang JH, Lee JS, Lee JW, Ahn MJ.

Cancer Res Treat.?2013 Dec;45(4):343-8. doi: 10.4143/crt.2013.45.4.343. Epub 2013 Dec 31.

Tumor Lysis Syndrome in a Solid Tumor: A Case Report of a Patient with Invasive Thymoma

Lee JY1¹,?Lim SH1,?Lee JY1,?Kim JH1,?Choi KH1,?Park K1,?Sun JM1,?Ahn JS1,?Ahn MJ1.

J Thorac Oncol. 2013 Nov;8(11):1409-16. doi: 10.1097/JTO.0b013e3182a46bcf.

Health-Related Quality of Life in Patients with Advanced Nonsquamous Non-Small-Cell Lung Cancer Receiving Bevacizumab or Bevacizumab-Plus-Pemetrexed Maintenance Therapy in AVAPERL (MO22089)

Rittmeyer A1¹, Gorbunova V, Vikstr?m A, Scherpereel A, Kim JH, Ahn MJ, Chella A, Chouaid C, Campbell AK, Barlesi F.

Anticancer Res.?2013 Nov;33(11):5127-33.

High-throughput Molecular Genotyping for Small Biopsy Samples in Advanced Non-small Cell Lung Cancer Patients

Maeng CH1¹,?Lee HY,?Kim YW,?Choi MK,?Hong JY,?Jung HA,?Lee KS,?Kim H,?Kwon OJ,?Sun JM,?Ahn JS,?Park K,?Um SW,?Ahn MJ.

J Clin Oncol. 2013 Aug 20;31(24):3004-11. doi: 10.1200/JCO.2012.42.3749. Epub 2013 Jul 8.

Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: AVAPERL (MO22089)

Barlesi F1¹, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikstrom A, Wong EK, Perez-Moreno P, Mitchell L, Groen HJ.

Eur J Nucl Med Mol Imaging. 2013 Jul;40(7):1005-13. doi: 10.1007/s00259-013-2400-4. Epub 2013 Apr 18.

Metabolic response evaluated by F-18-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy

Moon SH1¹, Cho SH, Park LC, Ji JH, Sun JM, Ahn JS, Park K, Choi JY, Ahn MJ.

Ann Oncol. 2013 Jun;24(6):1630-9. doi: 10.1093/annonc/mds649. Epub 2013 Feb 7.

Prospective analysis of quality of life in elderly patients treated with adjuvant chemotherapy for non-small-celll lung cancer

Park S1¹, Kim IR, Baek KK, Lee SJ, Chang WJ, Maeng CH, Hong JY, Choi MK, Kim YS, Sun JM, Ahn JS, Park K, Jo J, Jung SH, Ahn MJ.

N Engl J Med. 2015 Oct 15;373(16):1582. doi: 10.1056/NEJMx150036.

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

¹,[No authors listed]

Lung Cancer. 2013 Mar;79(3):300-6. doi: 10.1016/j.lungcan.2012.11.010. Epub 2012 Dec 21.

Epidermal growth factor receptor mutation and treatment outcome of mediastinoscopic N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery

Ahn HK1¹, Choi YL, Han JH, Ahn YC, Kim K, Kim J, Shim YM, Um SW, Kim H, Kwon OJ, Sun JM, Ahn JS, Park K, Ahn MJ.

J Thorac Oncol. 2013 Mar;8(3):373-84. doi: 10.1097/JTO.0b013e31827ed0ff.

Epidermal Growth Factor Receptor Inhibition in Lung Cancer Status 2012

Hirsch FR1¹, Janne PA, Eberhardt WE, Cappuzzo F, Thatcher N, Pirker R, Choy H, Kim ES, Paz-Ares L, Gandara DR, Wu YL, Ahn MJ, Mitsudomi T, Shepherd FA, Mok TS.

Med Oncol. 2013 Mar;30(1):479. doi: 10.1007/s12032-013-0479-x. Epub 2013 Feb 3.

Clinical outcomes of atypical carcinoid tumors of the lung and thymus: 7-year experience of a rare malignancy at single institute

Han B1¹, Sun JM, Ahn JS, Park K, Ahn MJ.

J Thorac Oncol. 2013 Feb;8(2):185-91. doi: 10.1097/JTO.0b013e3182773f21.

Leptomeningeal Carcinomatosis in Non-Small-Cell Lung Cancer Patients Impact on Survival and Correlated Prognostic Factors

Lee SJ1¹, Lee JI, Nam DH, Ahn YC, Han JH, Sun JM, Ahn JS, Park K, Ahn MJ.

J Mol Diagn. 2013 Jan;15(1):51-61. doi: 10.1016/j.jmoldx.2012.08.006. Epub 2012 Dec 12.

Multiplexed Gene Expression and Fusion Transcript Analysis to Detect ALK Fusions in Lung Cancer

Lira ME1¹, Kim TM, Huang D, Deng S, Koh Y, Jang B, Go H, Lee SH, Chung DH, Kim WH, Schoenmakers EF, Choi YL, Park K, Ahn JS, Sun JM, Ahn MJ, Kim DW, Mao M.

Lung Cancer. 2013 Jan;79(1):40-5. doi: 10.1016/j.lungcan.2012.10.002. Epub 2012 Oct 25.

Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer

Lee HY1¹, Ahn HK, Jeong JY, Kwon MJ, Han JH, Sun JM, Ahn JS, Park K, Choi YL, Ahn MJ.

Cancer. 2012 Dec 15;118(24):6234-42. doi: 10.1002/cncr.27630. Epub 2012 Jun 6.

Gefitinib Versus Pemetrexed as Second-Line Treatment in Patients With Nonsmall Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy (KCSG-LU08-01)

Sun JM1¹, Lee KH, Kim SW, Lee DH, Min YJ, Yun HJ, Kim HK, Song HS, Kim YH, Kim BS, Hwang IG, Lee K, Jo SJ, Lee JW, Ahn JS, Park K, Ahn MJ; Korean Cancer Study Group.

Eur J Cancer. 2012 Nov;48(17):3198-204. doi: 10.1016/j.ejca.2012.06.009. Epub 2012 Jul 13.

A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01)

Ji JH1; Korean Cancer Study Group (KCSG)¹, Yun T, Kim SB, Kang JH, Park JC, Cho IS, Sohn CH, Heo DS, Jang JS, Shin SW, Hwang DW, Sun JM, Park K, Ahn MJ.

Cancer Chemother Pharmacol. 2012 Aug;70(2):315-20. doi: 10.1007/s00280-012-1876-0. Epub 2012 Jul 4.

Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation

Cho SH1¹, Park LC, Ji JH, Park S, Hwang DW, Lee JY, Choi YL, Han JH, Sun JM, Ahn JS, Park K, Ahn MJ.

Lung Cancer. 2012 Aug;77(2):346-52. doi: 10.1016/j.lungcan.2012.03.011. Epub 2012 Apr 23.

Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer

Ahn MJ1¹, Yang JC, Liang J, Kang JH, Xiu Q, Chen YM, Blair JM, Peng G, Linn C, Orlando M.

J Oral Pathol Med. 2012 May;41(5):415-23. doi: 10.1111/j.1600-0714.2011.01105.x. Epub 2011 Nov 14.

Reappraisal of KIT mutation in adenoid cystic carcinomas of the salivary gland

Sung JY1¹, Ahn HK, Kwon JE, Jeong H, Baek CH, Son YI, Ahn YC, Park K, Ahn MJ, Ko YH.

J Clin Oncol. 2012 Apr 1;30(10):1122-8. doi: 10.1200/JCO.2011.36.8456. Epub 2012 Feb 27.

First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

Han JY1¹, Park K, Kim SW, Lee DH, Kim HY, Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, Lee JS, Yoon SJ, Han JH, Lee JW, Jo SJ, Lee JS.

Hum Genet.?2012 Mar;131(3):365-72. doi: 10.1007/s00439-011-1080-z. Epub 2011 Aug 25.

The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations

Ahn MJ1¹,?Won HH,?Lee J,?Lee ST,?Sun JM,?Park YH,?Ahn JS,?Kwon OJ,?Kim H,?Shim YM,?Kim J,?Kim K,?Kim YH,?Park JY,?Kim JW,?Park K.

Lung Cancer. 2012 Jan;75(1):82-8. doi: 10.1016/j.lungcan.2011.05.022.

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy

Kim ST1¹, Uhm JE, Lee J, Sun JM, Sohn I, Kim SW, Jung SH, Park YH, Ahn JS, Park K, Ahn MJ.

J Cancer Res Clin Oncol. 2011 Aug;137(8):1203-11. doi: 10.1007/s00432-011-0986-0. Epub 2011 May 28.

Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy

Lee S1¹, Kim Y, Sun JM, Choi YL, Kim JG, Shim YM, Park YH, Ahn JS, Park K, Han JH, Ahn MJ.

Oral Oncol. 2011 Aug;47(8):714-9. doi: 10.1016/j.oraloncology.2011.06.007. Epub 2011 Jun 25.

Insulin-like growth factor binding protein-3, in association with IGF-1 receptor, can predict prognosis in squamous cell carcinoma of the head and neck

Sun JM1¹, Jun HJ, Ko YH, Park YH, Ahn YC, Son YI, Baek JH, Park K, Ahn MJ.

Cancer Chemother Pharmacol. 2011 Aug;68(2):531-8. doi: 10.1007/s00280-010-1522-7. Epub 2010 Nov 25.

Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats

Sun JM1¹, Nam MH, Chung JY, Im B, Lee SY, Suh YL, Ahn JS, Park K, Ahn MJ.

J Thorac Oncol. 2011 Aug;6(8):1392-9. doi: 10.1097/JTO.0b013e3182208ea8.

Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherapy

Sun JM1¹, Han J, Ahn JS, Park K, Ahn MJ.

Lung?Cancer.?2011 Jul;73(1):63-9. doi: 10.1016/j.lungcan.2010.10.019. Epub 2010 Nov 18.

New CT response criteria in non-small cell lung cancer: Proposal and application in EGFR tyrosine kinase inhibitor therapy

Lee HY1¹,?Lee KS,?Ahn MJ,?Hwang HS,?Lee JW,?Park K,?Ahn JS,?Kim TS,?Yi CA,?Chung MJ.

Asia Pac J Clin Oncol. 2011 Jun;7 Suppl 2:13-21. doi: 10.1111/j.1743-7563.2011.01398.x.

An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia

Chang JW1¹, Thongprasert S, Wright E, Tsang K, Kim HT, Ahn MJ, Kim JH, Kang JH, Kim SW, Walzer S.

Asia Pac J Clin Oncol. 2011 Jun;7 Suppl 2:22-33. doi: 10.1111/j.1743-7563.2011.01399.x.

Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan

Ahn MJ1¹, Tsai CM, Hsia TC, Wright E, Chang JW, Kim HT, Kim JH, Kang JH, Kim SW, Bae EJ, Kang M, Lister J, Walzer S.

Asia Pac J Clin Oncol. 2011 Jun;7 Suppl 2:34-40. doi: 10.1111/j.1743-7563.2011.01400.x.

Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes

Chang GC1¹, Ahn MJ, Wright E, Kim HT, Kim JH, Kang JH, Kim SW, Sherman S, Walzer S.

J Cancer Res Clin Oncol. 2011 Apr;137(4):687-94. doi: 10.1007/s00432-010-0928-2. Epub 2010 Jun 16.

The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients

Sun JM1¹, Won YW, Kim ST, Kim JH, Choi YL, Lee J, Park YH, Ahn JS, Park K, Ahn MJ.

Cancer. 2011 Jan 1;117(1):143-51. doi: 10.1002/cncr.25560. Epub 2010 Aug 27.

Clinical Impact of Amphiregulin Expression in Patients With Epidermal Growth Factor Receptor (EGFR) Wild-Type Nonsmall Cell Lung Cancer Treated With EGFR-Tyrosine Kinase Inhibitors

Chang MH1¹, Ahn HK, Lee J, Jung CK, Choi YL, Park YH, Ahn JS, Park K, Ahn MJ.

Oncology. 2010;79(1-2):78-84. doi: 10.1159/000320190. Epub 2010 Nov 12.

Prognostic Model to Predict Outcomes in Non-Small Cell Lung Cancer Patients with Erlotinib as Salvage Treatment

Kim ST1¹, Lee J, Sun JM, Park YH, Ahn JS, Park K, Ahn MJ.

Lung Cancer. 2010 Sep;69(3):330-6. doi: 10.1016/j.lungcan.2009.11.015. Epub 2009 Dec 14.

Unsuspected pulmonary emboli in lung cancer patients: The impact on survival and the significance of anticoagulation therapy

Sun JM1¹, Kim TS, Lee J, Park YH, Ahn JS, Kim H, Kwon OJ, Lee KS, Park K, Ahn MJ.

J Thorac Oncol.?2010 Aug;5(8):1185-96. doi: 10.1097/JTO.0b013e3181e2f624.

Korean Ethnicity as Compared with White Ethnicity Is an Independent Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer before and after the Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Era

Ahn MJ1¹,?Lee J,?Park YH,?Ahn JS,?Ziogas A,?Zell JA,?Park K,?Ou SH.

Lung Cancer. 2010 Jul;69(1):105-9. doi: 10.1016/j.lungcan.2009.09.014. Epub 2009 Dec 2.

Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors

Sun JM1¹, Ahn MJ, Park MJ, Yi JH, Kim TS, Chung MJ, Park YH, Ahn JS, Park K.

Cancer. 2010 Jun 15;116(12):3025-33. doi: 10.1002/cncr.25130.

Comparison of Gefitinib Versus Erlotinib in Patients With Nonsmall Cell Lung Cancer Who Failed Previous Chemotherapy

Kim ST1¹, Lee J, Kim JH, Won YW, Sun JM, Yun J, Park YH, Ahn JS, Park K, Ahn MJ.

Lung?Cancer.?2010 May;68(2):258-63. doi: 10.1016/j.lungcan.2009.06.008. Epub 2009 Jul 9.

Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases

Kim KH1¹,?Lee J,?Lee JI,?Nam do H,?Kong DS,?Ahn YC,?Park HC,?Kwon OJ,?Kim H,?Chang MH,?Yi SY,?Ji SH,?Park YH,?Ahn JS,?Park K,?Ahn MJ.

Cancer. 2010 Feb 1;116(3):676-85. doi: 10.1002/cncr.24748.

Clinical Impact of Phosphorylated Signal Transducer and Activator of Transcription 3, Epidermal Growth Factor Receptor, p53, and Vascular Endothelial Growth Factor Receptor I Expression in Resected Adenocarcinoma of Lung by Using Tissue Microarray

Kim HS1¹, Park YH, Lee J, Ahn JS, Kim J, Shim YM, Kim JH, Park K, Han J, Ahn MJ.

Cancer. 2010 Jan 1;116(1):132-6. doi: 10.1002/cncr.24719.

Multicenter Phase 2 Study of Belotecan, a New Camptothecin Analog, and Cisplatin for Chemotherapy-Naive Patients With Extensive-Disease Small Cell Lung Cancer

Lee DH1¹, Kim SW, Suh C, Lee JS, Ahn JS, Ahn MJ, Park K, Na II, Lee JC, Ryoo BY, Yang SH.

APMIS.?2009 Dec;117(12):861-9. doi: 10.1111/j.1600-0463.2009.02545.x.

Prognostic role of insulin-like growth factor receptor-1 expression in small cell lung cancer

Chang MH1¹,?Lee J,?Han J,?Park YH,?Ahn JS,?Park K,?Ahn MJ.

Med Oncol. 2009;26(3):287-91. doi: 10.1007/s12032-008-9117-4. Epub 2008 Nov 7.

The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma

Hong JY1¹, Choi MK, Uhm JE, Park MJ, Lee J, Park YH, Ahn JS, Park K, Han JH, Ahn MJ.

J Thorac Oncol. 2009 Jul;4(7):809-15. doi: 10.1097/JTO.0b013e3181a94af4.

Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer

Park S1¹, Holmes-Tisch AJ, Cho EY, Shim YM, Kim J, Kim HS, Lee J, Park YH, Ahn JS, Park K, Janne PA, Ahn MJ.

J Biol Chem. 2009 Jul 24;284(30):20099-110. doi: 10.1074/jbc.M109.010017. Epub 2009 Jun 1.

House Dust Mite Allergen Der f 2-induced Phospholipase D1 Activation Is Critical for the Production of Interleukin-13 through Activating Transcription Factor-2 Activation in Human Bronchial Epithelial Cells

Park SY1¹, Cho JH, Oh DY, Park JW, Ahn MJ, Han JS, Oh JW.

Anticancer Res. 2009 May;29(5):1817-22.

Clinicopathological Implications of EpCAM Expression in Adenocarcinoma of the Lung

Kim Y1¹, Kim HS, Cui ZY, Lee HS, Ahn JS, Park CK, Park K, Ahn MJ.

Cancer.?2009 Apr 1;115(7):1518-30. doi: 10.1002/cncr.24151.

Prognostic Model to Predict Outcomes in Nonsmall Cell Lung Cancer Patients Treated With Gefitinib as a Salvage Treatment

Park MJ1¹,?Lee J,?Hong JY,?Choi MK,?Yi JH,?Lee SJ,?Oh SJ,?Ahn JS,?Park K,?Ahn MJ.

Oncology. 2009;76(4):239-46. doi: 10.1159/000205386. Epub 2009 Feb 25.

Comparison of Survival in Advanced Non-Small Cell Lung Cancer Patients in the Pre- and Post-Gefitinib Eras

Kim HS1¹, Park K, Jun HJ, Yi SY, Lee J, Ahn JS, Park YH, Kim S, Lee S, Ahn MJ.

Cancer. 2008 Sep 15;113(6):1379-86. doi: 10.1002/cncr.23693.

ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy

Hwang IG1¹, Ahn MJ, Park BB, Ahn YC, Han J, Lee S, Kim J, Shim YM, Ahn JS, Park K.

Clin Cancer Res. 2008 Jun 15;14(12):3860-6. doi: 10.1158/1078-0432.CCR-07-4608.

Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer

Ahn MJ1¹, Park BB, Ahn JS, Kim SW, Kim HT, Lee JS, Kang JH, Cho JY, Song HS, Park SH, Sohn CH, Shin SW, Choi JH, Ki CS, Park CK, Holmes AJ, Janne PA, Park K.

APMIS. 2006 Sep;114(9):619-25.

Phospho-Stat3 expression and correlation with VEGF, p53, and Bcl-2 in gastric carcinoma using tissue microarray

Choi JH1¹, Ahn MJ, Park CK, Han HX, Kwon SJ, Lee YY, Kim IS.